Annual Report 2006 Annual Report 2006

Annual Report 2006 The Garvan’s mission is to make significant Project Manager Dr Branwen Morgan contributions to medical science that will Design + Production change the directions of science and medicine Turnbull Ossher Design and have major impacts on human health. Photography Garvan strives to enhance and develop Richard Weinstein Photography research programs that combine fundamental Published April 2007 science with strong clinical interactions. We wish to acknowledge Turnbull Ossher Design for the generous gift of the Annual Report 2006 design and thank them for their continuing and valuable support.

Further Acknowledgements Garvan Research Foundation

Copies of the Annual Report can be obtained by contacting: Gabriella O’Neil Email [email protected] Telephone + 61 2 9295 8120 More information about our research and our staff can be found on Garvan’s website: www.garvan.org.au

During 2007, further website changes will be made to reflect the more efficient and increased use of the online medium. Table of Contents

Who We Are, What We Do 2 Institute Highlights 4 Chairman’s Report - Garvan Institute 6 Executive Director’s Report 9 Chairman’s Report - Garvan 12 Research Foundation Organisation Chart 15

Commercialisation & Biotechnology 16

Management Reports 18

RESEARCH REPORTS

Cancer Research Program 22

Diabetes & Obesity Research Program 28

Immunology & Inflammation 32 Research Program Osteoporosis Research Program 36

Neuroscience Research Program 40

Autoimmunity Research Unit 44

Pituitary Research Unit 48

Garvan Community 52 Institute Governance 58 Foundation Governance 61 Publications 64 Financial Report 70 The Garvan Institute of Medical Research is a world leader in its field, pioneering study into many of the widespread diseases affecting our community today. Research at Garvan is focused on understanding the role of genes in health and disease as the basis for developing future cures.

Significant breakthroughs have been achieved by Garvan scientists in the understanding and treatment of diseases such as:

Cancer Diabetes and obesity Alzheimer’s and mental illness Osteoporosis Arthritis and asthma Autoimmune diseases Pituitary tumours and disorders

Garvan’s ultimate goal is prevention and cure of these major diseases.

WHO WE ARE WHAT // WE DO The Garvan Institute of Medical Research is a world leader in its field, pioneering study into many of the widespread diseases affecting our community today. Research at Garvan is focused on understanding the role of genes in health and disease as the basis for developing future cures.

Significant breakthroughs have been achieved by Garvan scientists in the understanding and treatment of diseases such as:

Cancer Diabetes and obesity Alzheimer’s and mental illness Osteoporosis Arthritis and asthma Autoimmune diseases Pituitary tumours and disorders

Dr Greg Cooney, Professor Roger Daly, Dr Bronwyn Hegarty, A/Professor Chris Ormandy A/Professor Hegarty, Dr Bronwyn Roger Daly, Professor Dr Greg Cooney, Making Connections: our metabolism, diabetes, and cancer researchers Scientific collaboration between seemingly unconnected conditions light on the associations between is shedding new Left to right: Formulating a new concept for how cancer cells can escape normal growth controls: they switch off large regions of genes that normally function to prevent tumour development Determining that a novel plant toxin can dramatically enhance the ability of tamoxifen to kill breast cancer cells Finding increased expression of ‘metabolically harmful’ genes in abdominal fat which may be one of the missing links between increased abdominal fat and type 2 diabetes Awarding of the Australian Diabetes Society’s highest award, the Kellion Award, to Professor David James Providing scientific evidence that a traditional Chinese medicine has beneficial effects for people suffering from type 2 diabetes Identifying that cortactin represents a marker of drug resistance in head and neck cancer Dr Sanda Biankin receiving the 2007 Gus Nossal Medical and Dental Postgraduate Research Scholarship given annually to the highest ranked NHMRC medical and dental postgraduate research applicant Publishing over 140 papers with an average impact factor of 6.7 ( > 8.0 for the top 75%)

INSTITUTE HIGHLIGHTS 2006 //

Finding that one of the earliest steps in immune system activation relies on a fatty acid binding molecule, which implicates diet in the functioning of the immune system Identifying novel methylated genes/regions in ovarian cancer with potential diagnostic significance Raising $1.13 million from a fundraising evening held by CRI in late September for Garvan’s Peter Wills Centre for Bioinformatics, which models and predicts diseases by applying information science to biology Showing that peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity and discovering that low levels of PYY in humans may contribute to subsequent weight gain and type 2 diabetes from theAustralian InstituteofPolicy andScience Dr StuartTangye receivingaYoung Tall Poppy Award controls inflammatoryresponsesintheairways ofasthmatics Discovering thatthefattyacidbindingmoleculeaP2 of cancerspreadingarevery high in low levels atthetimeofsurgery, meansthechances Identifying anew prostatecancermarker thatiffound acquired deafness rise tonew hearing-like nerve cellsthatarelostin Discovering thatadultolfactorystemcellscangive // disease, whichoftengoeshandinwithtype2diabetes cells –resistancetowhichcouldcontributecardiovascular Unearthing a newly recognised effect of insulin on inflammatory cause ofbetacelldeathisendoplasmicreticulumstress Discovering thatinhumandiabetesanunderlying applicant inthefieldofdiabetes Career Development Award forbeingthehighestscoring Dr JennyGuntonreceivingtheprestigiousDART/NHMRC protects animalmodelsfromdeveloping type1diabetes populations involved inpresentingbetacellproteinstoTcells Demonstrating how changingspecificgenesinparticularcell Grant toourImmunology&InflammationResearchProgram Awarding ofa$15millionfive year NHMRCProgram mechanism linkingcentralbrainactivityandbonemass regulating osteoblastfunction,therebyidentifyinganovel Describing theroleofneuropeptideY1receptorin and theNSWOfficeofScienceMedicalResearch one osteoporotic fracture fractures inwomen andespecially inmenwhohave hadjust Determining thatthereisa highriskoffurtherosteoporotic that willhelpthedesignof atestforgrowth hormonedoping Completing amajorstudy in over 100recreationalathletes for MedicalResearchscientific meeting overall presentationattheannualAustralian Society for Excellence inMedicalResearch’given forthebest Lowenna Holtwinningthe‘University ofSydney Medal development ofthiscancer may have importantimplicationsforunderstandingtheearly and inprecancerouscolontumourscalled‘serrated polyps’ Showing thatMCCgenesilencinginasubsetofbowel cancer

INSTITUTE HIGHLIGHTS CHAIRMAN’S REPORT REPORT CHAIRMAN’S A further$11millionwas addedtotheInstitute’s longtermendowment fund. (to bespreadacrossthreeyears) andbequestsof$10million.Puttingasidethese identified inourcancerresearchprojects. to aCancerDevelopment Unittoleadcommercialvalidationofthemany‘targets’ to develop anew CancerResearchCentrewithSt Vincent’s Hospital;andcommitted holding facilityforexperimental mousemodelsintheSouthernHighlands;agreed papers andinternationalawards. We alsofinalisedplansforamajorbreedingand excellent recordofresearchsuccessasmeasuredbyachievements suchasgrants, 2006 was another highlysuccessfulyear fortheGarvanInstitute.We continuedour 2006 in generalandspecificgrantscontributedtoGarvanresearchprograms. through theGarvanResearchFoundation, essentialinproviding criticalequipment the additionofnew groupsinourmajorresearchareas.Philanthropicsupport and reflectsgrowth intheresearchactivitiesof existing groups,togetherwith acknowledges the impressive progressofGarvanresearchover thepastdecade the previous year (adjustedforanumberofone-offgrants).This increase Garvan’s operatingincomein2006was $49.1million,includingacapitalgrant Financial Performance the nation’s researchenterprise. governments oftheimportanceandvalueinvestment inthisareatounderpin Garvan continuestoleadeffortswithinthemedicalresearchsectorconvince to provide thecritical supportservicescannotkeep pacewiththegrowth inresearch. a furtherfundingdifficultyfortheInstituteinthatinfrastructurenecessary for peer-reviewed grants.While very pleasedwithoursuccessinthisarea,itcreates The cornerstoneofanyleadingresearchinstituteisitslevel ofsuccessincompetition Scholarships andAwards to thefacultyandouroutstandingmorejuniorresearchers. were alsorecognisedagainin2006withrecordnumbersofprestigious Fellowships, It was particularlypleasingtoseethattheexcellence anddedicationofGarvanstaff helped ensurethatourimportant relationshipwiththeUniversity remainedstrong. Dean ofMedicine,completed theirshorttenureontheBoard,duringwhichthey Mark Wainwright asActingVice Chancellorand ProfessorRichardHenry, asActing appointment asDeanofMedicineatUNSWandjoinedthe Boardmid-year. Professor University ofNew SouthWales nominees.ProfessorPeter Smithtookuphis The onlychangestothecompositionofBoardduringyear relatedtothe a cohesive groupofindividualsdedicatedtothecontinuingsuccess Institute. One ofthemanystrengthsGarvanisitstalentedand highlycommittedBoard– The Board from thefederalgovernment, anadditional$2millionfromtheNSWGovernment and facilitatingnew initiatives, continuedtobestrongwithover $2.5million one-off items,ouroperatingincomegrew to$36.9millionfrom0 /

REPORT CHAIRMAN’S / detection, diagnosisandtreatmentofcancer. is toimprove patientoutcomesinthe scientists. The objective ofourresearch clinicians, clinicalresearchersandbiomedical practice bybringingtogetherthehighestquality a facilityofinternationalstandingandglobalbest programs inthecountry. Ourvisionistocreate strength asoneoftheleadingcancerresearch This initiative allows ustobuild upon ourexisting government andpublicsupportforcancerresearch available forresearchuse,togetherwithstrong with extensive databasesandclinicaltissuebanks 2) Australia’s well-developed publichealthsystem and treatmentofcancer for personalisedapproachestotheprevention of cancerandtheconcomitantopportunities and biomarker informationaboutsubtypes 1) Recognitionoftheexplosion ofgenetic Development oftheCentreisinresponseto: one ofSydney’s leadingteachinghospitals. with therenowned clinicalcareofStVincent’s, internationally recognisedcancerresearch The CentrewillhelpintegrateGarvan’s Street, adjacenttothecurrentGarvanbuilding. develop aCancerResearchCentreonVictoria agreement between GarvanandStVincent’s to the Campusoccurredinlate2006withaformal The firststepinanother exciting initiative for we arenow experiencing. This willhelprelieve thespacepressures than 80Garvanresearchersinourmainbuilding. building, spacewillbecomeavailable formore and Victor ChangresearchgroupsfromtheGarvan Following completionofthenew building design ofthenew building. months tointegratevariousneedsintothe progress hasbeenmadeover thepasttwelve service operationsandmaintenance.Significant to becateredforincludeinformationtechnology, cell sortingfacilities.Otherimportantfunctions the state-of-the-artmicroscopy, genechip,and the sharingofcorescientificfacilities,suchas tasks indevelopment ofthePrecinctistooptimise scientific facilities.Oneofthemostimportant Vincent’s researchgroupsandseveral shared building tohousetheVictor ChangInstitute,St construction was startedonthenew research After several years ofplanningandfundraising, commitment tothevaluesofSistersCharity. close associationwithStVincent’s Hospitalandits of theStVincent’s Campusandcontinuesits The GarvanInstituteisanactive member Campus Developments in early2008,andrelocationofStVincent’s

I amdelightedtoconfirmthatDrLisaMcIntyre valuable insightintocommercialisationofourresearch. and BoardmemberDrLisaMcIntyrewhoprovided to theexpertise andeffortsofPaul Bell,Peter Carre funding streamsforourresearch.We areindebted disease prevention. Italsohelpsattractfuture translated intoimprovements inpatientcareand ensure thatourresearchbreakthroughsareeffectively was particularlyactive. Successinthisareahelps biotechnology–pharmaceutical landscape, through thecomplexities oftherapidlychanging established in2004tohelpguidetheInstitute The BusinessDevelopment AdvisoryCommittee, our coreresearch. validation ofpromisingfindingsemanatingfrom initially intheCancerProgram,toleadcommercial has resolved toestablish specific‘development units’, in 2008.Asadirectresultofthissuccess,theBoard the past12monthsandisontargetforclinicaltrials inflammatory antibodyhasprogressed very well over and Novo Nordisk,thedevelopment ofakey anti- between Garvan spin-off companyG2Therapies relationships. Inparticular, throughthepartnership in ourpatentportfolioandongoingsuccessindustry health care.2006was characterised bystronggrowth research discoveries intorealoutcomesforimproved is increasinglybeingmatchedbyprogressintranslating Garvan’s successinourbasicresearchprograms Business Development in additiontoitscriticalongoingfundraisingactivities. a priorityfortheGarvanResearchFoundation, Such initiatives arekey toGarvan’s futureandform Research Fellowship. towards establishingtheDonChisholmDiabetes in Neuroscienceandsecuredearlycommitments enhanced bycreationoftheCurranFoundation Chair Ritchie Fellowship. During2006,thisinitiative was Petre ChairinBreastCancerResearchandtheBill generosity ofmajordonorsandestablishmentthe we have madesignificantprogressthroughthe and retainthetopinternationaltalent.Inrecentyears establishing endowed researchpositionstoattract infrastructure hashighlightedtheimportanceof and theconstantchallengeofsecuringmatching The growth oftheInstitute’s research programs Endowments for theFuture of Australia. our researchfortheeconomicandsocialbenefit to provide animportantavenue tofurtherdevelop and biotechnologygroupsduring2006continued Ongoing relationshipswitharangeofpharmaceutical of theAdvisoryCommittee. has now agreedtotake over theroleasChair

CHAIRMAN’S REPORT CHAIRMAN’S REPORT an additional$10millionwas provided mid-2004, thepasttwo years have in aspecificTCMandelucidationofits finding ofsubstantialanti-diabeticaction witnessed exciting progressinour signing oftheformalAgreementin Chinese Medicines(TCMs).Following Biological SciencesfocusedonTraditional alliance withtheShanghaiInstitutesof of thisinternationalreachisourongoing expertise. Avery promisingexample technologies andcomplementary often facilitatingouraccesstoemerging research andfinancialopportunities with overseas groupsprovides both in internationalactivities.Collaboration importance ofbeingsignificantlyinvolved research institutes,we recognisethe As oneofAustralia’s leadingmedical International Initiatives of ourresearchtothecommunity. that we remainabletodeliver thebenefits program ofresearchsupporttoensure will continuetopressforanequitable with theothermajorNSWinstitutes, the coreissueunresolved. Garvan,together providing sometemporaryreliefbutleaving This was onlya ‘one-off’ commitment, As adirectresultofthisinitiative, to theprovision ofresearchsupport. for anexpanded andstructuredapproach in ajointproposaltotheNSWGovernment with theothermajorNSWinstitutes and toformulateasolution,we joined afloat. To addressthisfundamentalissue our research,theharderitisforustostay of success’;thatis,themoresuccessful referred tothisfundinggapasthe‘riddle to carryouttheresearch.Ihave previously awarded, uptoanother70centsisrequired For every dollarofresearchfunding provided bycompetitive researchgrants. cost ofdoingresearchandthefunding Australia isthegap between thetotal successful researchinstitutesaround One ofthemajorchallengesfacing Funding and relevance ofourresearch. collaborations, reflectingthestatus to have significantinternational All ofGarvan’s programscontinue therapeutic properties. to examine other TCMswithreported resulted inanexpansion ofourcollaboration mechanism ofaction.This successhas in the2006NSWStateGovernment budget.

deliver continuing success. supporters, Iamconfidentthat2007will growing number ofourcorporateandcommunity of Garvanresearchers,theBoardand Nevertheless, withtheongoingcommitment increase inbothfinancialandhumanresources. with healthcaredelivery butwillrequireamajor potential tointegrateourresearchmoreclosely the CancerResearchCentre,offerenormous Several importantnew initiatives, particularly pressure arisingfromoursuccessandgrowth. as ourinfrastructureisplacedunderever-increasing an exciting andchallengingoneforGarvan The year aheadwillundoubtedlybeboth 2007 Garvan InstituteofMedicalResearch Chairman Bill Ferris AO

REPORT DIRECTOR’S EXECUTIVE disorders. New momentum was similarlyaddedtoourDiabetes questions indiabetes,arthritis,asthmaandotherautoimmune us to form an impressive critical mass of expertise to tackle important groups transferringfromtheCentenaryInstitute.This hasallowed growth toover 400staffwas theaddition ofleadingimmunology collaboration acrossourprograms.Aparticularhighlightof most withcross-disciplinaryknowledge tohelpusstimulate In 2006,we recruited manyleadingscientistsintheirfields, 2006 play animportantroleinourquesttoimprove qualityoflife. at theforefrontofinternationaladvancesandcontinuesto these resultsdemonstratethatourresearchisbenchmarked between research discoveries andrealadvancesin healthcare, are difficulttomeasureduetheinherentlongtimeframe of ourinternationalpublications.Althoughresearchoutcomes We alsofinishedthe year witharecordforboththenumber our internationalandothernationalcompetitive funding. for 2007,withover $14millionofNHMRCfundingtocomplement Health and Medical Research Council (NHMRC) ensuring a solid base application result(almostdoublethenationalaverage) totheNational year fortheInstitute. This was evidenced byanimpressive grant with expansion of existing projects,resultedinavery successful ranging fromdiabetestoParkinson’s. These new initiatives, together trafficking. This work hasimplicationsformanyGarvanprojects, from theUSAresearchingfundamentalbasisofcellularprotein & ObesityProgramwiththerecruitmentofamajornew group (146) andsignificance(impactfactorof>8forthetop75%) /

EXECUTIVE DIRECTOR’S REPORT EXECUTIVE DIRECTOR’S REPORT 10 medicine hasbeneficialeffectsintype2 other researchachievements aredescribed studies intheworld. These andthemany longest runningosteoporosisepidemiology Osteoporosis Study–now oneofthe system; andongoingdatafromtheDubbo diet ineffective functioning oftheimmune obesity; afindingthatstronglyimplicates of aparticularneuropeptideleadsto diabetes; thediscovery thatloss that aparticulartraditionalChinese cancer progression;scientific evidence of anew molecular marker ofprostate and epigeneticsofcancer;theidentification to ourunderstandingofthegenetics These included:significantcontributions outstanding researchachievements. 2006 witnessedseveral Research Outcomes grants, scholarshipsandawards. and younger investigators inattaining success ofmanyournew recruits scientists, we were heartenedbythe by largerprogramsandmoreestablished In additiontothefundingattracted effects ofosteoporosis. insights intothecausesanddebilitating which continuestoprovide unique the futureofthisimportantproject, (commercial andphilanthropic)toensure able tosecureothersourcesoffunding attract. Fortunately, we have now been term studiesarenotoriouslydifficultto at risk.Grantfundingforsuchvery long- was adisappointingexception, placing funding oftheDubboOsteoporosisStudy grant applications,ourrequestforongoing by impressive success incompetitive Although 2006was largelycharacterised in detailtheResearchProgramReports. our 15-year commitmentinthisarea

autoimmune disordersanddeterminingtheroles mechanisms underlyingthedevelopment of Mackay, theUnitiselucidating molecular Unit. UndertheleadershipofProfessorFabienne to establishaseparateAutoimmunity Research over thepasttwo years provided theopportunity national andinternationallyleadinggroups as aconsequenceoftherecruitmentseveral The rapidexpansion ofourimmunologyresearch Autoimmunity Research Unit Development Approval andisunderconstruction. which hasreceived Wingecarribee shireCouncil mouse breedingandholdingfacilityinMossVale, Garvan asawholewillbenefitfromthenew our mostpromisingcancerresearchprojects. of aCancerDevelopment Unittocommercialise area, theGarvanBoardapproved thecreation Also improving our potentialimpactinthecancer strength withStVincent’s clinicalknowhow. a collaborationthatwillcombineourresearch Cancer ResearchCentreonVictoria Street, St Vincent’s Hospitaltodevelopment anew core ofGarvan’s activities.We agreedwith and clinicalresearchoutcomesthatlieatthe Several otherimportantmilestonesattained New initiatives and/or treatment. individual patientstotherightclinicaltrials This work suggeststheremay beways totarget category ofBcell-dependentlupuspatients. levels intheirserum.They may fallintoanew who have elevated BcellActivatingFactor (BAFF) clinical implicationswiththe20-5%ofpatients mediated byBcells.This work hasimportant uncovered anew formoflupus,whichissolely establishment inmid2006,theUnithasalready of differentfamiliesimmunecells.Sinceits during 2006willhelpusreachthescientific

and some20%involve StVincent’s Hospital Anniversary Dinner (over $1.million)towards for compoundsthatimprove insulinaction. with HarvardMedicalSchooltoscreen We have alsoinitiatedanexciting collaboration medicines andgrowth hormonedoping. ventures inovarian cancer, traditionalChinese genetic epidemiologyinosteoporosisandjoint national consortiainbreastandprostatecancer, and Airways, BioimagingandDairyCRCs), major Cooperative ResearchCentres(Asthma studies. The latterincludeparticipationinthree colleagues) andpartnershipinmajorcollaborative researchers fromotherAustralian institutions papers involve overseas collaborators,40%include by bothourresearchoutputs(nearly50%ofGarvan Our successinthisendeavour isevidenced of importancetoAustralia. and resourcestoaddressthecomplex diseases to bringtogethercomplementaryexpertise national andinternationalcollaborationsdesigned places considerableimportanceoneffective competitive researchgrantprocesses,Garvan in medicalresearchworldwide andhighly In today’s environmentofrapidprogress Collaborative Research for Bioinformatics. the ongoingoperationsofPeter Wills Centre note, was theamount raisedattheCRI of theGarvanResearchFoundation. Of particular increasing supportfromfundraisingefforts 2006, allfacilitieswere widelyusedandreceived upgraded asnew technologiesdevelop. During behavioural analysis facilitieswhichareconstantly cell sorting,histology, clinicalresearchand bioinformatics, genearray, genepolymorphism, These includesophisticatedmicroscopy, St Vincent’s CampusandaroundAustralia. wherever possibletoourcollaboratorsonthe are available toall ourresearchprogramsand places apriorityonensuringthatsuchfacilities in diseaseinitiationandprogression.Garvan and quantificationofmoleculescellsinvolved for thevisualisation,measurement,identification program isaccesstostate-of-the-artfacilities Key tothesuccessofanymodernmedicalresearch Core Scientific Facilities

the successesof2006.Ourexpanding activities and ourmanycorporateindividualsupporters. the staff, theBoardsofInstituteandFoundation that we have anabundanceofsuchindividuals– people involved. Garvanisparticularlyfortunate primarily ontheexcellence anddedicationofthe Our ongoingsuccessinmedicalresearchdepends into improved healthandqualityoflife. effectively translate researchbreakthroughs research enterprisetoensurethatwe most position intheAustralian andinternational we willwork totake fullopportunityofour elucidating thefundamentalbasisofdisease, While Garvanremainsclearlyfocusedon careful prioritisationofourresearchdirections. will involve pressureonexisting resourcesand the considerablemomentumgeneratedfrom challenging fortheGarvanaswe buildupon The comingyears shouldbeexciting and 2007 Garvan Institute ofMedicalResearch Executive Director Professor JohnShine AO FAA

EXECUTIVE DIRECTOR’S REPORT CHAIRMAN’S REPORT 12 REPORT CHAIRMAN’S to establishaChairinNeuroscience,plusmajorbequestsof$10millionmade years, theFoundation hasraisedbetween $3millionand$5sothisyear most importantly, grow ourendowment fundbyanadditional$11million. of $870833andspecificprogramcontributions$1.7millionand, we have beenvery fortunate.Amajorgiftof$1millionfromtheCurranFoundation in its150thanniversary year inAustralia, contributedagrandtotalofover $42000 increased from177to97.Mostnotably, therewas anincreaseincompanies We areproudtoreportthatthenumberoforganisationsgivingGarvanalso whom Garvancouldnotfulfilitsmissiontoachieve breakthroughmedicalresearch. individuals whomadegiftsof$1000ormore.We thankallourdonorswithout In 2006,3084individualdonorschosetomake agifttoGarvanincluding119 made undertheleadershipofournew Director. the supportwe have received fromourdonorsandtheprogresswe have Foundation’s 2006resultswell exceeded ourexpectations intermsofboth On behalfoftheBoard,Iamvery pleasedtoreportthattheGarvanResearch Garvan ResearchFoundation On thisbasiswe have beenabletomake ourannualgranttotheInstitute up thebulkofincome. The Foundation’s totalincomefor2006was over $14.5million.Typically inpast donations madebyitsemployees withatotalgiftofover $36000duringtheyear. through staffdonationsandgenerousmatchinggiftsfromthebank.CSRalsomatched of supportfrombusinessesandtheiremployees. BNPParibas, forexample, providing support throughpayroll givingprograms,ahighlyeffective form grateful toourgenerousdonors whohave leftlegaciestoGarvan intheirwills. of researchersandclinicians working closertogether. We are,therefore,enormously Health toestablishaCancerResearch Centresothatpatientscanreceive thebenefits of New SouthWales, orourproposed jointventure with StVincent’s andMater as ourstate-of-the-artmouse holdingandbreedingfacilityintheSouthernHighlands endowment fund,Garvancouldnothave contemplatedsuchfuture-orientedinitiatives operations. Itallows ustomake largeleapsforward inourprograms.Without the Building uptheendowment fundiscriticaltothefuturesustainabilityofGarvan’s from thelateDrsJamesandJosephineRyan. In particular, we were thebeneficiaryofa very significantbequestof over $9million 2006 hasbeenanexcellent year intermsofthegrowth ofourendowment fund. Bequests /

on how we candoaneven betterjobinthisarea. December 2006thatprovided valuablefeedback culminating withourdonorsurvey issuedin but we arepleasedtoreportgoodprogress, as possible.We stillhave some way togo, our servicetoindividualdonorneedsasmuch to maintainhighqualitydonorrecords,andtailor and systemstogetknow oursupporters, performance –implementingnew tools,procedures the Foundation teamworked hardtoliftourservice Garvan pridesitselfonourstewardship Improving ourservicetodonors initiative targetingtheUSwas launchedin2006. Diabetes ResearchTrust International.Afundraising JP MorganChase,theUSArmyandJuvenile funding fromsuchUS-basedbodiesas of timeandeffort.Garvanhaspreviously attracted significant over athree-to-five yearcommitment opportunities whichwe believe couldprove strong commitmenttomedicalresearch,offers The USphilanthropicenvironment,withits brand recognitioninourfieldsofresearch. many internationalcollaborationsandwide is alsoatrulyworld-class enterprise.We have foundations. While proudlyAustralian, Garvan goals istoattractsupportfromUS-based One oftheFoundation’s medium-to-long-term Attracting InternationalSupport and communitygroups. tours, anddelivered 30presentationstoschools participants onournow regularprogramofGarvan Community Awareness Programhostedabout1000 In thecourseof2006,ourPublicEducationand around 1700membersofthecommunity. of NSW. Taken together, bothinitiatives attracted seminar series,sponsoredbythePublicTrustee positive. The Foundation alsodelivered ouron-site high qualityinformationandeducationwas very Hill. Communityfeedbackonlocaldelivery ofour locations, includingGosford,Liverpool andCastle Diseases, ourseminarteamvisitednumerous Healthy Eating,Ageing,andAutoimmune and itsoutskirtsin2006.Covering suchtopicsas only on-siteatGarvan–‘on theroad’withinSydney our very popular public seminars–previously run We thankNestléAustralia forenablingustotake Community Information Services of relationswithdonorswhosupportus.In2006,

In 2006we were fortunatetohave DimityRaftos, identify andengagewithpotentialnew supporters. opportunities, itisimportantfortheFoundation to Given Garvan’s continuedstronggrowth andfuture Communicating withoursupporters a six-year period. We thankthemallmostsincerely. have bothablysupportedtheFoundation over endeavours over thatperiod.MrTait andMrScrimshaw years andhasmade anenormouscontributiontoour has served asaFoundation Boardmemberfortwelve Tait, andMrRussellScrimshaw. MrSims,inparticular, terms ontheBoardinearly2007:MrTim Sims,MrNick of ourlongest-serving Directorswhofinishedtheir I would like toexpress Garvan’s gratitudetothree grant tosupportthePeter Wills BioinformaticsCentre. dinner. They includeda$1millionFederal Government the beneficiaryoffundsraisedatits25thanniversary deserving ofmention.CRIchosetomake Garvan corporate supporterssuchasMLC andASXismost Similarly, theGarvan’s relationshipwithlong-standing in May, whichthehotelvery generouslysupported. community membersatadinnerthePark Hyatt We acknowledged theeffortsoftheseloyal (those whoplantomake agifttoGarvanintheirwill). wonderful volunteers andPartners fortheFuture our particularappreciationtotheFoundation’s I would like totake thisopportunitytoexpress Acknowledging long-term loyalty across theprogresswe areachieving. as atri-annualcommunicationtokeep everyone our formernewsletters andlaunched As abenefittosupporters, we alsoreviewed brought inover $277000forGarvanresearch. end ofyear appeals.Taken together, theseappeals our bestresultsever forbothourMay/June and We aregratefulforthepositive response,yielding developments inourresearchneedoffunds. the enhancementofourregularlettershighlighting Existing supporterswillnodoubthave noticed of scienceandmedicine. excitement ofdiscoveries thatcanchangetheface of ourGarvancommunityandbegantoshareinthe to disease.In2006,1950new donorsbecamepart who mightcaretoassistGarvanfindtheanswers expertise tothetaskofreachingmorepeople Family, joinoursmallteam,bringinghighlyprofessional formerly DirectMarketing ManageratThe Smith breakthough

CHAIRMAN’S REPORT CHAIRMAN’S REPORT 14 to ourMCsfortheyear, Andrew O’Keefe Professor HerbertHerzog.Thanks also Kathryn Eisman,AshleighSynnottand Professor Fabienne Mackay, Paula Joye, Reynolds, Professor GordianFulde, Ken Ho,DrAntonyKidman,Siimon Jack Szczepina,DanielMurphy, Professor including DrDave Martin,Peter Beacroft, Our thanksgototheforumpanellists, image. These were very well attended, on dopinginsport,stressandbody three educationalforumsfocusing Fellowship. The YGCommitteeorganised over $32500towards theYoung Garvan another successfulyear in2006,raising year oldSydney professionals,enjoyed Young Garvan,ournetwork of2 5-35 Young Garvan results, intheyear ahead. continued support,andtoeven better over thepastyear. Ilookforward toyour for theirvaluablecontributiontoGarvan every memberoftheFoundation Board, member oftheFoundation team,and Finally, letmethankevery donor, each needs arebestserved. that bothoursupporters’andGarvan’s the compositionofteamtoensure Carole Renouf, continuestoreview Manager. OurFoundation Director, recruited DimityRaftosasDirectMarketing contributions toGarvan.We successfully We thankJerryandSusanfortheir the SupporterServicesManagerrole. position, andRachaelStewart assumed Susan Sussemsalsomoved ontoanew assumed thePACE Managerrolefull-time. left ustogooverseas andDanielleFischer During thecourseof2006,JerryFrenkel Staffing We arevery grateful. his financialsupportbehind Young Garvan. of theWebb GroupofCompaniesthrow Most significantly, 2006saw MrBenWebb them backintheyears tocome. We lookforward towelcoming Saunders fortheircontribution. Sutton, CassieLapointeandDarren Committee andourthanksgotoLauren There ismovement ontheYoung Garvan and DrDarrenSaunders. attracting 135new participants toGarvan.

Garvan Research Foundation Chairman Graham Bradley Garvan Institute Organisational Chart Chair: MrBillFerris AO Board ofDirectors Garvan InstituteofMedical Research Commonwealth &NSW HealthMinisters University ofNSW Trustees ofStVincent’s Hospital Sisters ofCharity

Pieter Huveneers MolecularImaging Peter Wills Bioinformatics Centre Gene Chip Cytofluorometry Clinical Research Biological Testing Genetics ofCancer ACRF Unitfor Molecular Core Research Facilities Mr JohnDakin Chief Operating Officer Development &SupportGroup Professor JohnShine AO FAA Executive Director Ms Carole Renouf Chief Executive Officer Garvan Research Foundation Chair: MrGraham Bradley Board ofDirectors Garvan Research Foundation Dr JeffFreeman Operations Mr JimMcBride Information Technology Ms MagdalenaMalota Human Resources Ms CateSmith Grants Administration Ms CherryDutton Finance andAccounting Dr Branwen Morgan Communications Ms ChristinaHardy Legal Affairs Business Development & Dr Jenny Kingham Biological Testing Facility

Professor Fabienne Mackay Autoimmunity Research Unit Professor JohnEismanAO Osteoporosis Professor RobSutherlandFAA Cancer Professor HerbertHerzog Neuroscience Professor David James Diabetes &Obesity Professor CharlesMackay Immunology &Inflammation Professor Ken Ho Pituitary Research Unit A/ Professor ChrisOrmandy A/Professor LizMusgrove A/Professor SueHenshall Professor RogerDaly A/Professor SueClark Senior Scientists: Dr BryceVissel Dr AmandaSainsbury-Salis Dr Sharon Oleskevich Senior Scientists: Dr Carsten Schmitz-Peiffer Professor Ted Kraegen A/Professor Antony Cooper A/Professor Greg Cooney Professor DonChisholmAO Professor Lesley Campbell A/Professor Trevor Biden Senior Scientists: Dr StuartTangye Dr Jonathan Sprent FRSFAA Dr MichaelRolph Dr CecileKing Dr ShaneGrey Senior Scientists: Dr Tuan Nguyan Senior Scientists: Dr RobertBrink Professor Antony BastenAO FAA Senior Scientists: • InstitutionalBiosafety • HumanResearch Ethics • AnimalEthics&Experimentation Campus Committees • SeniorScientists • Seminars • Occupational Health &Safety • Publications • Information Technology • HigherDegrees • Director’s Executive • Building&Equipment • BTFPolicy Advisory • Appointments&Promotions Institute Committees • Investment • Finance &Audit • BusinessDevelopment Advisory Board Committees Pty LtdandG2Therapies Ltd. spin-out companiesAZAResearch Garvan isashareholder inthe Innovative DairyProducts. Biomedical Imagingand for AsthmaandAirways, Garvan isapartnerintheCRCs 15

ORGANISATION CHART Overview The Business Development team, under the leadership of Christina Hardy, collaborates with the pharmaceutical and biotech sector and partners with other academic organisations to take Garvan’s research discoveries one step closer towards the development of new treatments and diagnostic tests. Working closely with Garvan scientists, the Business Development team is responsible for all aspects of commercialisation from monitoring research activities to maximising early capture of intellectual property, identifying biotech market opportunities, and negotiating and managing commercial agreements. The team also assists the researchers with non-commercial activities such as setting up academic collaborations and transferring scientific material. Patents have been filed in the treatment, diagnostics and screening categories.

41% Neuroscience [15] 28% Cancer [10] 17% Diabetes [6] 8% Immunology [3] 6% Bone [2]

Patent Portfolio by Garvan Research Program Contact: Christina Hardy; p 02 9295 8132; [email protected]

16 COMMERCIALISATION & BIOTECHNOLOGY /

G2 Therapies and Novo Nordisk G2 Therapies is a private company, chaired by Dr John Schubert, which develops and commercialises antibody-based therapeutics for inflammation. Founded at Garvan in 2002, major investors include AMWIN, and Baron Nominees. In early 2006, G2 announced the signing of a major research, development and licensing agreement with Danish healthcare company Novo Nordisk. The terms of the agreement include an upfront payment, success-based payments to a potential total of around US$100 million (A$135 million), and royalties on commercialised therapeutics. The partnership will enable the new therapy to be taken through to human clinical trials. Development work for the first year progressed extremely well and will continue through 2007. & BIOTECHNOLOGY COMMERCIALISATION / Garvan InstituteofMedicalResearchBoardChairman, Bill Ferris AO, The currentcouncilmembersare: biotech andpharmaceuticalindustry. Institute ChairmanBillFerris, includesseveral representatives fromthe The BusinessDevelopment AdvisoryCouncil(BDAC), chairedbyGarvan Business Development AdvisoryCouncil Group Leader, CancerResearchProgram Dr SueHenshall, IP Manager, Garvan Lisa Hilder, Chief OperatingOfficer, Garvan John Dakin, Director, BusinessDevelopment &LegalAffairs,Garvan Christina Hardy, CEO, BurrillAustralia Peter Carre, Director, L.E.K.Consulting Dr LisaMcIntyre, External Director Paul Bell, Executive Director, Garvan Professor JohnShineAO FAA, Garvan ResearchFoundation BoardDirector

COMMERCIALISATION & BIOTECHNOLOGY 18

Linking up: & Support Our Development pride in providing Groups take and a best practice framework operating environment for our involves scientists. This sharing learnings with similar organisations around the globe MANAGEMENT REPORTS // REPORTS MANAGEMENT MANAGEMENT REPORTS MANAGEMENT Left to right: Jim McBride, Jim Ogden, Natasha James, Lisa Moncur

Highlights

Reaching a staffing level of over 400 Obtaining extensive news coverage of six major research stories and providing media training Gaining Wingecarribee Shire Council approval for to key scientific spokespeople an initiative to develop an offsite mouse breeding and holding facility in Moss Vale, NSW (to operate Producing a 10 minute film, the Garvan virtual as Australian BioResources) that will also be a resource tour, that can be viewed on the website for other research institutes Finalising new institute branding guidelines to give Extending the capacity within the existing Garvan the institute a more recognisable and professional look animal facility, as an interim measure to deal with Implementing the GeneSpring WorkGroup server - space shortages, to accommodate an extra 500 cages, a system that saves and stores gene-chip experiment and to test new state-of-the-art equipment (biobubbles) results. This system has been made available to, Remodelling and expanding laboratories and is in use by, researchers across NSW on levels 5, 7, 8 & 10 Upgrading Garvan’s computer network and servers, Implementing a staff OH&S legislation and rolling out a new sophisticated file storage solution awareness initiative - saving Garvan real dollars in online disk storage Upgrading the OH&S systems including Implementing new mobile phone technology with the development of a new risk management phone plans that will reduce call costs between staff software package ‘SafeG’ Designing and releasing brand-new web-based Completing plans for a new cafeteria on level 8 grants administration and safety management information systems Commencing the new precinct (Victor Chang) building, which will join Garvan at levels 3, 4, & 7 Completing CanSto - a cancer clinical and lab information system - for Garvan’s pancreatic research Upgrading the security systems to include video surveillance for a safer and more secure Licensing versions of CanSto to the Hanson Institute working environment in Adelaide and Monash University in Melbourne Receiving approximately 16 000 different products Installing an online donations page on Garvan’s website and handling 8500 external purchase orders 19

MANAGEMENT REPORTS MANAGEMENT REPORTS 20 honorary appointments(suchasDoctorsandPathologists) andvisitingstudents. Associates includethefollowing categoriesofappointees:visitingscientists, Staff -breakdown bycategory Garvan hasnow grown to403staffmembers(asatDec1,2006): Staffing Wills BioinformaticsCentre. Cytofluorometry Facility, PieterHuveneers Molecular Imaging Unit,andthe Peter Affymetrix GeneChipFacility, BiologicalTesting Facilty, ClinicalResearchFacility, Operations; andseven corefacilities:ACRF UnitfortheMolecularGeneticsofCancer, Administration, Finance &Accounting,HumanResources,InformationTechnology, of seven groups:BusinessDevelopment &LegalAffairs,Communications,Grants delivery tothem and tosupporttheoverall functioning oftheorganisation.DSGiscomprised The needsofGarvanresearchersarecomplex andwe constantlystrive toimprove services by providing services, facilitiesandinfrastructureinanefficienttransparentmanner. The Development &SupportGroup’s goalistoenhancethescientific work atGarvan 307 Garvanstaff, 44associates,52students.Ofthe307Garvanstaff, 242arefulltime. Students Associates 59% 41% 52 44 403 Female [239] Male [164]

35 Mr JimMcBride mathematics, statisticsandcomputer sciencetounderstand,organiseandanalysebiologicaldata. Peter Wills Bioinformatics Centre Dr Will Hughes not possible. intermolecular events atthesurfaceofindividuallivingcells aresolutionandspeedpreviously based techniques.Ournewest microscope,thefirstofitskind,allows scientiststoimagemultiple cells orintracellularorganellesandmoleculesusingavariety oftransmittedlightandfluorescence- Pieter Huveneers MolecularImagingUnit Dr JeromeDarakdjian as purecultures,usedtoextract RNAorDNAforgeneticanalyses,implanted intoanimalmodels. separated onthebasisofmultiplephenotypicandfunctional characteristics,canthenbegrown populations ofcelltypesfromanybodyfluidortissuesuspensio n. The purepopulationofcells, Cytofluorometry Facility Angela Peris for osteoporosismedications. Staff alsomonitorvolunteers involved inpharmaceuticalclinicaltrials,suchasthose (e.g. growth hormone,sex steroidhormones,insulin)ondifferentmetabolicsystems. Clinical ResearchFacility Dr JennyKingham to enablequalityanimal-basedresearch. Biological Testing Facility Professor CharlesMackay large numbersofsamples.Garvanwas thefirstin Australia toestablishthesystem. of interest,thesubsetswhichcanthenbefurtheranalysedinACRF Unitthat canhandle to comparethelevels ofgenetranscriptsintissuesamples.Itisusedtofindpotentialgenes Gene ChipFacility Dr Vanessa Hayes expression, andmethylationonalargescale.Itisusedbycancerresearchersthroughoutthestate. equipment thatcandetectandanalysegeneticsequencevariationssuchasgenelosses,mutations, Australian CancerResearchFund(ACRF) Unitfor theMolecularGeneticsofCancer used byinternalscientistsandexternal researchers,thelatteronapay perusebasis. necessary experiments tobetterunderstanddiseaseprocesses.Amanageroversees thefacilities research facilitiescontainstate-of-the-artequipmentthatenablesourscientiststoperformthe Technology isanimportantcomponentofbeingcompetitive inmedicalscience.Garvan’s core Core Research Facilities e: [email protected] e: e: [email protected] containstheAffymetrixMicroarray Systemthatisused e: [email protected] e: [email protected] [email protected] e: [email protected] compriseshighspeedcellsorterstoallow theseparationofuptofour runsGarvanclinicalprojectsthatlookattheeffectofhormones holdsthemouseproductioncoloniesandprovides specialisedzones e: [email protected] appliestechniquesderived fromdisciplinessuch asapplied p: 92958232 consistsof5microscopescapableimagingtissue, p: p: p: p: 92958175 92958232 92958345 92958145 p: 92958432 p: 9295840

houses

MANAGEMENT REPORTS

Genetic clues: timely and tailored treatment is one of the goals Early detection of cancer that allows cancer researchers. Professor Rob Sutherland and Dr Sandra Biankin share of Garvan’s in pancreatic and prostate cancer with supporters Tracey of discoveries the excitement Jacobson Hon Justice Peter Spicer and The RESEARCH REPORT // REPORT RESEARCH CANCER PROGRAM CANCER

Research Program Research CANCER CANCER Professor Rob Sutherland FAA Our People of the elected a Fellow Associate Professor Susan Clark was for Biotechnology her contribution Network Technology World finalists for the 2006 selected as one of five to Epigenetics and was the most innovative that acknowledges Award Technology World people in the science and technology world promoted to Conjoint Professor at UNSW Roger Daly was nominated as a recipient of research award was Hayes Dr Vanessa of banking in Australia to celebrate 125 years from BNP Paribas Nossal Medical and the 2007 Gustav awarded Dr Sandra Biankin was annually to the highest Research Scholarship given Dental Postgraduate NHMRC medical and dental postgraduate research applicant ranked Our success with funding from the Cancer Institute NSW continued, Krishan Naylor, Matthew Millar, to Drs Ewan awarded with fellowships Rasiah, Christopher Scarlett and Jack Zhao; postgraduate scholarships Anderson, Dr Sandra Biankin, Emily Colvin, Maria Kalyuga, to Luke and Johanna Susanto; a joint Translational Rebecca Hinshelwood, which includes Garvan Program Grant in Colorectal Cancer, & Lisa Horvath) and major Sydney (Drs Maija Kohonen-Corish hospitals and research facilities a PhD scholarship by the Australian awarded was Liz Tindall Rotary Health Research Fund, International District 9680, South Wales of New and the University Medal for Excellence of Sydney the ‘University Holt won Lowenna presentation at the for the best overall in Medical Research’ given Society for Medical Research scientific meeting annual Australian Director:

23 Showing that MCC gene silencing Showing cancer and in in a subset of bowel precancerous colon tumours called important have ‘serrated polyps’ may implications for understanding of this cancer the early development methylated Identifying novel cancer genes/regions in ovarian with potential diagnostic significance technique Describing a novel for high-throughput testing of genetic of the human genome markers prostate cancer Identifying a new levels that if found in low marker means the at the time of surgery, chances of cancer spreading are high very that half of oestrogen- Discovering regulated genes are also by c-Myc, indicating that Myc is likely to be particularly important in the control as breast loss of growth cancer develops Identifying that cortactin represents of drug resistance in head a marker and neck cancer

Tracey Spicer, Dr Sandra Biankin, Professor Rob Sutherland, The Hon. Peter Jacobson Hon. Peter Rob Sutherland, The Dr Sandra Biankin, Professor Spicer, Tracey Left to right: Highlights Our Work plant toxin Determining that a novel can dramatically enhance the ability to kill breast cancer cells of tamoxifen molecular markers Employing subgroup of poor to define a new prognosis breast cancers of Wt1 that overexpression Showing can disrupt the endocrine response in breast cancer cells, and so possibly proliferation contribute to excess and failure to differentiate during of breast cancer the development Establishing that prolactin acts during early stages of mammary the very cell proliferation carcinogenesis to drive in pre-cancerous lesions, resulting in a faster progression to carcinoma concept for how a new Formulating cancer cells can escape normal growth switch off large regions controls: they of genes that normally function tumour development to prevent CANCER Research Program 24 anti-oestrogen medication,tamoxifen, intheclinic. cycle andsocouldbeinvolved inresistancetothe genes thatmightlinkoestrogenactionwiththecell Translational Groups,we arealsosearchingfornew with theSteroidHormoneActionandBreastCancer that actupstreamofcyclinD1.Incollaboration in breastcancer, we have beenstudyinggenes cycle genecyclinD1isfrequentlyoverexpressed is lostinbreastcancercells.Sincethecell machinery andhow controlover thecellcycle in how thesehormonesactonthecellcycle in thebreast.We areparticularlyinterested progesterone stronglyinfluencecellreproduction Female steroidhormoneslike oestrogenand Group Leader: Cell Cycle of breastandothercancers. development asnew therapiesforthetreatment in breastcancercells.This couldleadtotheir compounds derived fromplantsinduceapoptosis cells. Otherprojectsincludeexamining how novel such astamoxifen caneffectively killbreasttumour these genesmay influencethe way anti-oestrogens this process.This willenableustounderstandhow this occursandidentifyingthegenesthatregulate apoptosis (celldeath).We areinvestigating how to proliferate,butitalsoprotectsthemfrom Oestrogen notonlycausesbreastcancercells Group Leader: Apoptosis BASIC CANCER RESEARCH breast, colorectal(bowel), lung,ovarian, pancreaticandprostate. study anumberofthemostcommonlydiagnosedtypescancer: Cancer ResearchProgramhasfive translationalresearchgroupsthat As well asbasicresearchintocellandmolecularbiology, theGarvan’s to stoptheformationandearlygrowth ofcancers. complex tissuestructures.With thisknowledge, we willbebetterable cell behaviours: theirdivision,survival,anddifferentiationinto we needtoknow muchmoreaboutthefundamentalprocessesthatgovern that canbeexploited toaiddiagnosis,treatment,andprognosis.To dothis, Although derived fromnormalcells,cancercellshave distinctive features AssociateProfessorLizMusgrove DrAlisonButt

Cancer geneticsisthestudyofgenetic Group Leader: Cancer Genetics of developing breast cancer. but wheninexcess canincreasetherisk cell proliferation, differentiationandlactation, that plays animportantroleinnormalmammary the genesthatrespondtoprolactin -ahormone therapies. Ourcurrentfocusis ondiscovering in theseprocessesmay provide targetsforfuture how theprogramgoesawry incancer. Key genes normal development ifwe aretounderstand We mustunderstandhow genesprogram function andsocontributingtothediseaseprocess. in breastcancer, alteringorsubverting theirnormal development canbecomemutatedordysregulated is thatthegenescontrolnormalmammary that regulatereproductive events. Ourhypothesis defined stagesthataregoverned bythehormones Development ofthemammaryglandoccursin Group Leader: Development treatment strategies. and indevelopment ofbetterdiagnosticand these cancerspriortotheonsetofsymptoms, identifying individualsathigh-riskofdeveloping population. Ourdiscoveries may beusefulin predisposition tothesecancersintheAustralian is partofanationwideprojectaimedatdetermining of breastand/orprostatecancer. Ourresearch that areassociatedwithanincreasedrisk action, withaview todiscovering geneticvariants that controlinflammationandregulatesex hormone Our groupisparticularlyinterestedinthegenes cancer riskandindividualresponsetotherapies. development andprogression,butalsoindividual genome sequencethatinfluencenotonlycancer of geneticvariations(mutations)withinthehuman with theidentificationandcharacterisation basis ofhumanmalignancies.We areconcerned DrVanessa Hayes AssociateProfessorChrisOrmandy

insulin-like growth factors. and growth-promoting effectsofinsulinand Grb14, andrelatedproteins,regulate themetabolic in theDiabetesProgram,we arestudyinghow in clinicaldevelopment. Together withresearchers protein increasesresistancetoanew drugcurrently and neckcancers,we have identifiedthatthis of cortactinarefoundinsomebreastandhead cancer cellspreadthroughoutthebody. Highlevels The lattereffectsuggeststhatGab2may promote of cancercellsbutalsotheirinvasive properties. cancers, increasesnotonlytheproliferation of Gab2,whichisfoundinasubsetbreast Gab2, cortactinandGrb14.Overexpression cell ortheregulationofthesesignallingevents: in eitherthetransmissionofsignalswithin Our researchfocusesonthreeproteinsinvolved Group Leader: Signal Transduction the development oftumours. regions may containgenesthatnormallyprevent try toreverse theprocess,aswe believe these work outthesequenceofevents sothatwe can during cancerdevelopment. We aretryingto can take placeacrossvery largeregionsofDNA have noticedthatthese‘epigenetic’changes methylation changesduringdevelopment and We have developed differentmethodstodetect demethylation between normalandcancercells. process thattriggersabnormalmethylationand Our researchfocusesonunderstandingthe by abiochemicalprocesscalledmethylation. Cancer cellsdeactivatelargeregionsofDNA Group Leader: Epigenetics ProfessorRogerDaly AssociateProfessorSueClark

Our researchaimstodetermineandcharacterise Group Leader: Steroid HormoneAction and responsetotherapy. genes arenew markers ofcancerprogression Groups, we have demonstratedthatsomeofthese In partnershipwiththeBreastandProstateCancer control ofcellproliferationanddeathinbreastcancer. a numberofsteroidregulatedgenesinvolved inthe Groups, we have identifiedandarecharacterising In collaborationwiththeCellCycleandApoptosis a thirdofallnewly diagnosedcancers. in steroid-responsive cancers,whichconstitute hormones oestrogen,progesterone,andandrogens the genesthatmediateactionsofsex steroid ProfessorRobSutherland

CANCER Research Program CANCER Research Program 26 cancer genesinthediseaseprocess. to definetheroleofnewly-discovered breast collaborative studies withotherinstitutions for treatmentfailure.We arealsoconducting loss ofresponsetotamoxifen isamajorreason molecular markers oftamoxifen resistance,since Steroid HormoneActionGroups,aimstoidentify A majorjointproject,withtheCellCycleand progression andresponsetoparticulartherapies. to identifymarkers ofdiseasesubtype, banks andpatientdatabasesthatarebeingused other hospitalswe have developed largetissue In associationwithcliniciansatStVincents and Group Leader: Breast Cancer CANCER RESEARCH TRANSLATIONAL of advanceddisease. potential novel therapeutictargetsfortreatment of ovarian cancer, andthereforemay alsoinclude likely includegenesthatcontrolthedevelopment for earlystageovarian cancer. These markers will genes thatmay have potentialasdiagnosticmarkers focus istheidentificationofapanelmethylated with theEpigeneticsGroup,ourcurrentprimary in thedevelopment ofovarian cancer. Together to understandthemolecularchangesinvolved a combinationofgeneticandepigeneticapproaches curable ovarian cancer. To thisend,we use ways todiagnosewomen withearlystage Our majorresearchgoalistoidentifynew Group Leader: Ovarian Cancer of new treatmentstrategies. gene defects,whichwillenabledevelopment understand thebiologicalsignificanceof at thehospitallaboratories.We alsowant to is todevelop geneticteststhatcanbeapplied carried outinclinicalpractice.Ouraim research laboratorybutthisisnotroutinely resected cancersortumourbiopsiesinthe Methylation canbeidentifiedfromsurgically mechanism promotingcancerdevelopment. methylation, apoorlyunderstoodmolecular new genesthatareinactivatedthrough and treatmentoutcomes.We have identified are themostusefulfordeterminingprognosis is towork outwhichkey genealterations outcomes arealreadyknown. The challenge specimens obtainedfrompatientswhoseclinical We examine thegeneprofilesofcancer Group Leader: Lung andColorectal Cancer ProfessorRobSutherland DrPipO’Brien DrMaijaKohonen-Corish

thirty years becausetherehasbeenlittle pancreatic cancerhasnotchangedforover The treatmentandsurvivalofpatientswith a five year survivalrateoflessthan10%. of cancerdeathinWestern societies,with Pancreatic canceristhefifthleadingcause Group Leader: Pancreatic Cancer the treatmentofadvancedstageprostatecancer. cancer orresistancetochemotherapy usedfor development ofaggressive life-threateningprostate whose expression changescanpredictthe Our researchaimstoidentifygenesandpathways Garvan, aswell as cliniciansandpathologists. of cancerresearcherswithinandoutsidethe approach thatutilisesexpertise fromanumber prostate disease.We take amultidisciplinary prognostic markers, andnew markers ofearly of markers fortherapeutic responsiveness, Our groupisconcernedwiththeidentification Group Leader: Prostate Cancer to pancreaticcancer. of retinoidsseeninleukemia andskincancer strategies thatmay extend thesuccessfuluse and definingnew diagnosticandtreatment signalling pathways inpancreaticcancer on understandingtheroleofretinoicacid associated withit.Ourprojectsfocus research intothemolecularandcellbiology DrAndrew Biankin AssociateProfessorSueHenshall

For additionalcontributorspleaseseepages54-55 National HealthandMedicalResearchCouncil National BreastCancerFoundation GO Fund Diabetes Australia ResearchTrust Cure CancerAustralia CRC forInnovative DairyProducts Clive &Vera RamaciottiFoundation Cancer InstituteNSW Fondation BNPParibas Boehringer Ingelheim Australian RotaryHealthResearchFund Australian ResearchCouncil Association forInternationalCancerResearch from thefollowing organisations: The CancerResearchProgramisgratefulforsupport FUNDING

Witchery University ofNSW US DepartmentofDefense The HillcrestFoundation The E.J.Whitten Foundation The CancerCouncilNSW Susan G.Komen BreastCancerFoundation Surgical ResearchSociety St Vincent’s ClinicFoundation RT HallTrust Royal HospitalforWomen Petre Foundation 27

CANCER Research Program

Modern Alchemy: with scientific rationale Blending traditional Chinese medicinal knowledge has captured the interest of scientists and supporters committed to finding therapies for type 2 diabetes new RESEARCH REPORT // REPORT RESEARCH DIABETES & OBESITY RESEARCH PROGRAM RESEARCH OBESITY & DIABETES Left to right: Professor David James, Dr Jiming Ye, Joseph Skrzynski AM, Dr Jane Li

Highlights Director: Professor David James

Our Work Our People

Developing novel technologies Discovering that in human Unearthing a newly Professor David James was awarded for watching the movement diabetes an underlying cause recognised effect of insulin the Australian Diabetes Society’s of blood sugar molecules into of beta cell death is endoplasmic on inflammatory cells – highest award - the Kellion Award living muscle and fat cells, aiding reticulum stress. resistance to which could Dr Carsten Schmitz-Peiffer our efforts to discover new molecules contribute to cardiovascular Further validating that inhibitors became a member of Garvan’s that participate in this process disease, which often of PKC epsilon are potential Senior Scientific Group goes hand in hand with Making inroads into the design treatments for diabetes type 2 diabetes Dr Greg Cooney was appointed of therapies to manage diseases, Identifying a lipid derivative as a NHMRC Senior Research Fellow such as type 2 diabetes and Identifying the reduced of phosphatidic acid that cardiovascular disease, which have production of a gut hormone contributes to insulin resistance insulin resistance as their root cause (PYY) in prediabetes which Finding increased expression may contribute to diabetes Identifying a new regulatory of ‘metabolically harmful’ genes and obesity input controlling insulin-stimulated in abdominal fat which may translocation of GLUT4 glucose Providing scientific evidence be one of the missing links transporter, a process that can that a traditional Chinese between increased abdominal be defective in diabetes medicine has beneficial fat and type 2 diabetes effects for people suffering Discovering the reduced from type 2 diabetes capacity of muscle to switch to oxidising or burning fat in the prediabetic state HIGHLIGHTS 29

DIABETES & OBESITY Research Program DIABETES & OBESITY Research Program 30 could bemoreusefulthancurrent therapeutics. to identifynew insulin-sensitisingagentsthat medicines withourcollaboratorsinShanghai We arealsodelvingintotraditionalChinese reduce fataccumulation. that activatethisenzymeandwhichcould of pharmaceuticalcompaniestoexamine drugs We have partnershipswithanumber the musclecell:whetheritisusedorstored. to controlthechoicemadebyfatonceitenters research isconverging onanenzymethatseems where itisburnedforenergy. Muchofour lipid oritischannelledintothemitochondria, are two choices.Itiseitherstoredasanintracellular When fatentersamusclecellfromblood there this informationtodevise strategiestoreduceit. control fataccumulationinmuscleandtouse Our majorfocusistounderstandfactorsthat Associate ProfessorGregCooney Group leaders: Insulin Action–Resistance for theregulationofproteintrafficking. controlled andareinvestigating themechanism cells, thedirectionandrateofwhichisprecisely by theconstantmovement ofproteinswithin and glucoseonthisjourney. We arealsointrigued to acell.Numerousproteinsinteractwithinsulin its ultimategoal:allowing glucosetogainentry it encountersitsfinaltarget,andhow itachieves from whenitbindstomuscleandfatcells methods touncover thepaththatinsulintakes is touseournewly-developed molecularimaging of nutrientsintoourmuscleandfatcells.Ourgoal defective intype 2 diabetesistheregulatedentry One ofthemajoractionsinsulinthatbecomes Group leader: Molecular Studies Insulin Resistance– in cellsandanimals, by metabolic disease, RNA silencing technologies to suppress gene expression of massspectrometrytoanalysetheproteomecellsandtissuesaffected disease states.Researchstrengthsincludelive cellmicroscopy, theuse metabolism, withanemphasisoninsulin’s modeofactioninnormaland program isfocusedonthemolecularregulationofbodyweight andfuel world tothepointwhereitisasignificanthealthissue.Researchinthis of obesity, bothofwhichhave increasedinAustralia andaroundthewestern The incidenceoftype2diabetesishighlycorrelatedwiththe ProfessorDavid James ProfessorTed Kraegen in vivo

genemanipulation,andclinicalstudies.

are conductingmicroarray analysesonfattissue the firstofthesequestions,ourresearchers changes predatethecondition?To address develop type2diabetesandwhatmetabolic Why dopeoplewithincreasedabdominalfat Professor Lesley Campbell Group leaders: Clinical Studies Insulin Resistance– diabetes andobesity. methods ofprevention ortherapy fortype2 their findingsshouldcontributetoimproved The studyofthesedifferentpopulationsand develop insulinresistanceandlipodystrophy. Centre whoareonHIVtherapy asmanyofthem They alsoinvolve peoplefromStVincent’s HIV very quickly, unlike peoplewhoareoverweight. because they convert fatstorestoenergy The metabolicstudiesinvolve peoplewithanorexia altered levels insubjectswithinsulinresistance. samples tofindwhichproteinshave significantly ProfessorDonChisholmAO

the cellsdealwithextra demands. to identifypotentialpointsofintervention tohelp stressors inducecelldeath,we may beable lead tocelldeath.Ifwe canelucidatehow these amounts ofunusableproteins,whichultimately of harmfulproducts,oraccumulatesunmanageable Either thecell‘burnsout’,generatesanexcess Huntington’s diseaseandParkinson’s disease. to agrowing numberofdiseasesincludingdiabetes, reticulum (ER).ERstressisdirectlyapplicable compartment calledtheendoplasmic misfolding ofproteinswithinacellular from theover-production ofproteinsand or failtocope,withthestressthatcanresult We want tounderstandhow cellscope, Group leader: Cellular Stress Imaging Facility. of theInstitute’s PieterHuveneers Molecular Much ofourwork isdonewiththeresources in disease,particular, diabetesandcancer. and how theseprocessesmay bedisrupted in signallingevents thatenablecellcommunication, are producedordestroyed, how they participate where, whenandwhyspecificphospholipids of proteinsintoandoutacell.We aimtoidentify ability toregulatethemovement anddistribution to affectthemembrane’s propertiessuchasits lipid compositionofmembranesistightlyregulated membranes. Itisbecomingclearerthattheexact (phospholipids) thatarethebuildingblocksofcell is concernedwiththelipidmolecules Our recently-established researchgroup Group leader: Phospholipid Biology For additionalcontributorspleaseseepages54-55 Juvenile Diabetes ResearchFoundation International Glaxo SmithKline Australia PtyLtd Eli Lilly Diabetes Australia ResearchTrust Diabetes Australia Cecilia Kilkeary Foundation AstraZeneca Australian Government’s InternationalScienceLinkagesProgram from thefollowing organisations: The Diabetes&ObesityResearchProgramisgratefulforsupport FUNDING DrAntonyCooper Dr Will Hughes

Swiss NationalFoundation Grant Rebecca CooperMedicalResearchFoundation Pfizer Novo Nordisk Novartis Stiftung National InstitutesofHealth(USA) National HealthandMedicalResearchCouncil response tofoodintake; skeletal musclewhich which make andsecreteinsulininaco-ordinated in wholebodyfueluse:thepancreaticbeta-cells Our work spansthemajortissuesimplicated Dr RossLaybutt Dr CarstenSchmitz-Peiffer Associate ProfessorTrevor Biden Group leaders: Diabetes Signalling that arelipid-responsive. insulin secretion,glucosehomeostasisandthose pathways thathave relevance totheconditioni.e. our groupsareprobingthesignaltransduction signalling pathways inoneormoreofthesetissues, or aberrantregulation,ofspecificintracellular As diabetescanbeviewed intermsofafailure, and clearsinsulinfromit. and liver, whichreleasesglucoseintothecirculation for thebulkdisposalofglucosefollowing ameal; is akey targetofinsulinand,assuch,accounts

DIABETES & OBESITY Research Program

32 es on how the immune es on how

New angles: New Our Immunology researchers are combining their unique perspectiv scientists fresh approach is changing how as protect us. Their system can cause disease as well and treat such problems view around the world RESEARCH REPORT // REPORT RESEARCH IMMUNOLOGY & INFLAMMATION RESEARCH PROGRAM RESEARCH INFLAMMATION & IMMUNOLOGY Left to right: Dr Cecile King, Professor Charles Mackay, Dr Jenny Gunton

Highlights Director: Professor Charles Mackay

Our Research Our People

Discovering that the fatty acid binding Dr Stuart Tangye received a Young Tall Dr Jenny Gunton was elected molecule aP2 controls inflammatory Poppy Award from the Australian Institute to the council of the Australian responses in the airways of asthmatics of Policy and Science and the NSW Diabetes Society Office of Science and Medical Research Publishing strategies for monoclonal Postdoctoral Fellow Dr Cindy Ma antibody production, which highlighted Professor Charles Mackay was promoted was awarded a NHMRC our C5aR work - the subject of our to NHMRC Principal Research Fellow Peter Doherty Postdoctoral major licensing deal with Novo Nordisk Research Fellowship Dr Jenny Gunton received the DART / Finding that one of the earliest steps NHMRC Career Development Award, Kim Good, a PhD student in in immune system activation relies which is awarded to the highest scoring the lab of Dr Tangye, was awarded on a fatty acid binding molecule, career development award applicant a Postdoctoral Fellowship from which implicates the diet in the in the field of diabetes Arthritis Australia to undertake functioning of the immune system postdoctoral training in the US Dr Shane Grey and Dr Jenny Gunton Revealing a novel signalling pathway were part of the team to win a program Dr Kate Jeffrey was awarded that has implications for the pathogenesis grant from the Juvenile Diabetes (jointly) the Garvan Thesis of X-linked lymphoproliferative disease Research Foundatation (JDRF) Prize 2006 for research into islet transplantation Identifying a critical role for the cytokine for the cure of type 1 diabetes IL-21 in regulating diverse subsets of human B cells. IL-21 and its receptor may be one of the important genetic elements for development of type 1 diabetes and other autoimmune diseases Awarding of a $15 million five year NHMRC Program Grant

HIGHLIGHTS 33

IMMUNOLOGY + INFLAMMATION Research Program IMMUNOLOGY + INFLAMMATION Research Program 34 Group leader: Arthritis andInflammation *Part oftheCRCforAsthmaandAirways can affectvariousaspectsofmetabolism. signalling moleculescalledcytokinesthat we now know thatinflammatorycellsrelease inflammatory andmetabolicdiseasesbecause 3. Lookingmorebroadlyatthelinksbetween fatty acidbindingproteinsandasthma; 2. Studyingthelinkbetween diet, monoclonal antibodiesastherapeutictools; for asthma,inparticular, todevelop 1. Developing new therapeuticapproaches We have threemainlinesofresearch: Group leader: Asthma* arthritis andmultiplesclerosis. control inflammatoryconditions,suchasasthma, of findingpointsintervention thatmay help pathways, againwiththeexpress purpose on dissectingtheimmunecells’signalling G2 Therapies Ltd.Otherprojectsarebased are beingcommercialisedbyGarvanspin-off intervene intheinflammatory processandthese have ledtodevelopment ofantibodiesthatcan development ofrheumatoidarthritis.Ourstudies of pain,inflammationandjointdamageinthe We aretryingtobetterunderstandtheprocess immunology andmetabolicsystems,cancerthenervous system. in otherprogramsoncross-disciplineprojectssuchasfindinglinksbetw new therapiestotreatdisease.We alsocollaboratewithGarvanscientists arthritis, autoimmunediseases,diabetesandasthma,alsotode situations. We hopetounderstandthebasisfordiseasessuchasrheumatoid Our researchersstudyaspectsofimmunefunctioninnormalanddiseased DrMichaelRolph ProfessorCharlesMackay

and afew live ontobecomememoryTcells, are overcome? We know thatmostself-destruct once theirmissioniscompleteandinfections homeostasis ishow arethesecellsdestroyed is centraltomaintainingtheimmunesystem’s antigens. Oneoftheunknown questionsthat to somehow distinguish between selfandforeign in avarietyofimmuneresponsesbutareable fate ofTcells-whitebloodthatparticipate Our teamisinterestedinthedevelopment and Group Leader: Cellular Immunity We arenow looking atways tocontrolARNT. glucose breakdown andinsulinproduction. genes involved inbeta-cellfunction,including It seemstobeamastergenethatcontrolsother cell containingisletsofpeoplewithtype2diabetes. ARNT, which isdecreasedby90%inthebeta We arecurrentlyfocussingonagenecalled cell functionandtherebytreathumandiabetes. cell failureoccursaswell asways toimprove beta transgenic micewe hopetoidentifywhybeta use ofavarietytissue-specificknockout and clues aboutwhatisgoingwrong.Through the in thesecells’geneexpression thatcanyield understood, butwe know therearechanges The causesofbeta-cellfailurearenotwell Group leader: Factors Diabetes andTranscription immune responsetotreatautoimmunediseases. tumours and,conversely, dampening down the immune systemtoboostitsattackoncancerous Application ofourwork liesinharnessingthe don’t know thefactorsthatdeterminetheirdestiny. which areactivatedbyare-infection,butwe DrJennyGunton ProfessorJonathanSprent velop

een

autoimmune diseasescouldbeattenuated. by whichtheimmunesystemofpatientswith in individualswithimmunodeficienciesand ways to identifymeansimprove theimmuneresponse that resultsinimmunodeficiency. Overall, we hope an inheritedX-linked lymphoproliferative disease will respondmorerapidly. We arealsostudying same infectiousagent,ourimmunesystems so thatfollowing subsequentexposure tothe it canprovideoftheresponse uswitha‘memory’ responds toinfectionsorvaccinations,suchthat in understandinghow theimmunesystem responses. We areparticularlyinterested antibodies -andtheregulationofantibody responsible fortheproductionofprotective of Bcells–thepopulationwhiteblood Our focusisonunderstandingthedevelopment Group Leader: Immunobiology of a‘death-defying’betacellasnovel cure. and, inthecaseoftypeIdiabetes,enablecreation to promotesuccessfulorgantransplantation toxic immunosuppressive drugscurrentlyrequired This strategywould alleviate theneedfor engineer tissuesthatcouldwithstandtheassault. hope of, oneday, beingabletogenetically that occurinthetissuebeingattacked inthe own cellsandinvestigating themolecularchanges factors thatregulatetheimmuneattackonour are destroyed. Approachesincludeexamining diabetes wheretheinsulin-producingbetacells grafts andinautoimmunedisorderslike typeI tissues asitoccursduringtherejectionoforgan why oftheimmunesystem’s attackonthebody’s Our laboratoryisinterestedinthehow and Group leader: Gene Therapy &Autoimmunity For additionalcontributorspleaseseepages54-55 Multiple SclerosisResearchAustralia Lupus AssociationofNSW Juvenile Diabetes ResearchFoundation International Diabetes Australia ResearchTrust Cooperative Research CentreforAsthmaandAirways from thefollowing organisations: The Immunology&InflammationResearchProgramisgratefulforsupport FUNDING DrShaneGrey DrStuartTangye

St Vincent’s ClinicFoundation Pfizer NSW MinistryforScienceandMedicalResearch National HealthandMedicalResearchCouncil our bodiesandtheenvironment.Broad-based that develop atthemucosalinterfacebetween that causeT1Dandotherautoimmunediseases interested intherelationshipbetween thecells they have beeninthebody. We areparticularly their dependenceupongrowth factorsandwhere markers thathelp ustodetermine,forexample, tissue-destructive Tcells.These cellsexpress beta cellsofthepancreasaredestroyed byself- In type1diabetes(T1D),theinsulin-producing Group leader: Mucosal Autoimmunity to beresponsibleformediatingtissueinjuryinMS. immune cells,termedThIL-17, whicharethought the activityofarecentlydefinedpopulation immune cellswithinthebrain(microglia)modulate repair. Studieshave focusedonhow resident injure brainandspinalcord,facilitatetissue spinal cordareregulatedsincethey canboth inflammatory responseswithinthebrainand Our work hasfocusedonunderstandinghow points toMSbeingapathogen-driven disease. and spinalcordanincreasingbodyofevidence MS isaninflammatorydiseaseofthebrain Group leader: Multiple Sclerosis (MS) suppression oftheseself-tissue-destructive cells. research istoidentifytargetmoleculesforselective immune systeminordertothrive. The aimofour obvious drawback sincewe needafunctioning diseases andtransplantrecipientsbutithasan suppression is commonly used to treat autoimmune DrCecileKing DrIanSutton

IMMUNOLOGY + INFLAMMATION Research Program

Cracking research: Cracking who is most at risk osteoporosis researchers are revealing Garvan’s brittle bones and that, after a first fracture, elderly of developing years. to refracture within just a few are equally likely men and women Dr Jackie Center demonstrates to Elizabeth Fyffe, and Michael by osteoporosis our bone scaffolding is destroyed how Foulsham Joy RESEARCH REPORT // REPORT RESEARCH OSTEOPOROSIS RESEARCH PROGRAM RESEARCH OSTEOPOROSIS Left to right: Dr Jackie Center, Elizabeth Fyffe, Michael and Joy Foulsham

Highlights Director: Professor John Eisman AO

Our Work Our People

Determining the high risk of further The Dubbo Osteoporosis Epidemiology Professor John Eisman Dr Paul Baldock was invited osteoporotic fractures in women and Study team was nominated was invited by the Australian to present a symposium topic especially in men who have had just for a Rhino Outstanding Business Government to be Co-chair at the 17th meeting of the one osteoporotic fracture Award from The Dubbo Chamber of the Arthritis and Osteoporosis International Bone and Mineral of Commerce in two categories: Expert Advisory Committee Society in Montreal, Canada Developing the first algorithm Excellence in Customer Focus and (AOEAC) and a member of the to identify absolute risk of a hip Dr Nguyen Nguyen was the Barnson Award for Excellence Expert Advisory Subcommittee fracture on an individual basis awarded a Young Investigator Product and Service (Finalist) of the Australian Population Award at The 33rd meeting Identifying the role of neuropeptide Health Developmental Principle Associate Professor Tuan Nguyen of European Calcified Tissue Y expression in the protection Committee was invited to give lectures at the Society (ECTS), Prague, of the skeleton from chronic stress first Symposium on Osteoporosis Dr Paul Baldock was awarded Czech Republic Describing the role of the neuropeptide in Vietnam August 2006 and received a fellowship from the Dr Nguyen Nguyen was Y1 receptor in regulating osteoblast a prestigious award from the Vietnam International Human Frontier awarded (jointly) the Garvan function, thereby identifying a novel Government “for his assistance Science Program Organisation Thesis Prize 2006 mechanism linking central brain and contributions to higher education to undertake studies in the function and bone mass and medical research in Vietnam” University Hospital, Geneva Postgraduate Scholar Dana Bliuc was awarded a Primary Associate Professor Tuan Nguyen Dr Paul Baldock received Health Care Scholarship from and Dr Nguyen Nguyen conducted an International Young the NHMRC a 3-day workshop in the design Investigator Award from the and analysis of clinical studies International Bone and Mineral for researchers at the University Society to speak at the Frontiers of Medicine and Pharmacy, of Skeletal Biology Conference Ho Chi Minh City, Vietnam in Davos, Switzerland HIGHLIGHTS 37

OSTEOPOROSIS Research Program OSTEOPOROSIS Research Program 38 new therapeuticpathways. increase ourunderstandingofbonebiology;andhelpidentify of theriskfactorsforfractures;find ways tobetterassesstreatments; strategy forreducingthisburden,we needtoimprove ourknowledge a largehumanandfinancialburden.Asprevention isthebest Osteoporosis affectsmostlyelderlymenandwomen andcarries

genes willhelpidentifytargetsfornovel therapies. these geneswork andinteractwithotherknown hormonal factors.Finding andunderstandinghow activity, dietaryhabits,medication,fall-relatedand into accountenvironmentalfactorssuchasphysical are atlow riskofosteoporosisandfractures–taking osteoporosis genesthatmay predictthosewho We arealsocontinuingtosearchfornew benefit mostfrompreventative interventions. risk offractureandtodeterminewhowould factors, toidentifymenandwomen athigh to develop predictive models,basedonmultiplerisk in menandwomen. We areusingtheDOESdata epidemiological studyofosteoporoticfractures and istheworld’s longestrunninglarge-scale Epidemiology Study(DOES),whichbeganin1989 Our researchdraws ontheDubboOsteoporosis and DrJackieCenter Group leaders: and Population Studies risk– Genetic,Individual Bone protection &fracture drug orvariouscombinationsofdrugs. are randomlyallocatedtoreceive anew participants whomeetspecificriskcriteria have afamilyhistoryofosteoporosis.Volunteer and volunteers who have hadafractureorwho of pharmaceuticaldevelopment. We recruitpatients potential treatmentsthatareinthefinalstages in multicentreinternationalclinicaltrialsevaluating Our clinicalstudiesgroupparticipates Group leader: Fracture Prevention -ClinicalStudies For additionalcontributorspleaseseepages54-55 Roche-GSK Eli LillyandCompany Organon deCODE genetics Amgen from thefollowing organisations: The OsteoporosisResearchProgramisgratefulforsupport FUNDING ProfessorJohnEismanAO AssociateProfessorTuan Nguyen

which influenceboneformationandstrength. of thebrainhormonesneuropeptideYandleptin, Our groupis,primarily, investigating therole regulated independentlyandinterdependently. of thecomplexity ofbone,they arelikely tobe genes areinvolved inbonehealth,butbecause bone formationandloss.Atleast20-30 It iscausedbyanimbalancebetween in bonedensityandthereforestrength. The hallmarkofosteoporosisisareduction Group leader: Bone Mass–Brain Regulation with researchersintheNeuroscienceProgram. models andiscarriedoutincollaboration Much ofwork makes useoftransgenicmouse Novartis Servier National HealthandMedicalResearchCouncil Sanofi Aventis Merck Sharpe&DohmeLimited

DrPaul Baldock

OSTEOPOROSIS Research Program

xperts

40 e anorexia

Measuring appetite: player. urge to eat is controlled by the brain, with neuropeptide Y being a key The Our Eating Disorders Research group brings together clinical and academic e Professor Janice Russell – University’s from outside the Institute - such as Sydney to further understand the role of appetite regulation in conditions lik RESEARCH REPORT // REPORT RESEARCH NEUROSCIENCE PROGRAM NEUROSCIENCE

Research Program Research

NEUROSCIENCE Dr Sharon Oleskevich was an invited was Dr Sharon Oleskevich at the Calyx- international speaker of-Held Symposium, Max Planck Institute, Leipzig, Germany a Training received Dr Sarah McKay from the Garnett Passe Fellowship Foundation Williams and Rodney an received Dr Bryce Vissel from the Ramaciotti award Foundation hosted the International We Advances in Brain Function Symposium

Professor Herbert Herzog Director: Our People plenary Professor Herbert Herzog gave Congress International 10th the at lectures and Australia on Obesity in Sydney, at the 2nd International Summit on Cardiometabolic Risk Associated Germany Intra-Abdominal Adiposity, With Garvan Neuroscience Program researchers and our collaborators presence made an impressive at the 8th International NPY Conference, Florida, USA, with invited presentations by Professor Herbert Herzog, Dr Amanda Karl, as well and Dr Tim Sainsbury-Salis, as symposia by PhD students Dana Boey, Susan Allison and Julie Wheway an invited Professor Herbert Herzog was symposia on: at a US Keystone speaker Gut Hormones and Other Regulators of Appetite, Satiety and Energy Expenditure

Dr Amanda Sainsbury-Salis, Dr Shu Lin, Professor Janice Russell, Professor Herbert Herzog Janice Russell, Professor Dr Shu Lin, Professor Dr Amanda Sainsbury-Salis, Left to right: Highlights Our Research adult olfactory stem cells Discovering nerve hearing--like rise to new can give cells that are lost in acquired deafness that peptide YY ablation Showing in mice leads to the development of hyperinsulinaemia and obesity Demonstrating that Y2Y4 receptor protects against double knockout obesity when fed a high-fat diet of PYY levels that low Discovering to insulin resistance in humans are linked contribute to subsequent weight and may gain and type 2 diabetes that conditional deletion Showing of hypothalamic Y2 receptors reverts bone loss gonadectomy-induced in adult mice molecule that Identifying a new regulates neurogenesis in the brain HIGHLIGHTS NEUROSCIENCE Research Program 42 fertility, mood,andweight gain. homeostasis (balancingenergyintake andexpenditure), whichaffects A key focusisthebetterunderstandingofbrain’s controlofenergy Alzheimer’s disease,schizophrenia,eatingdisorders,andhearingloss. of theneuronalsystemsinvolved indisorderssuchasParkinson’s disease, The NeuroscienceResearchProgramaimstoincreaseourunderstanding

nervosa andcancercachexia. dwarfism, andosteoporosis,as well asanorexia for thetreatmentofobesity, infertility, poorlactation, this system.Ourresearchfindingshave implications that regulateappetiteandbodyweight dosovia and itsY-receptors, sincemanyofthemolecules Our mainfocusisonneuropeptideY(NPY) in overweight orobesepeople. metabolic resistancetoweight lossoccurring nervosa andcancercachexia aswell asthe for causingwasting conditionssuchasanorexia that regulatetheseprocessesmay beresponsible are regulated.Defectsinthebrainpathways understand how appetiteandbodyweight One ofourlaboratory’s majorgoalsisto and DrAmandaSainsbury-Salis Group leaders: Eating Disorders those lostinParkinson’s orAlzheimer’s disease. of nerve cellsfoundinthebrain;forexample, to transformthemintothedifferenttypes cells, andofdeterminingtheconditionsneeded of identifying,isolatingandpropagatingthese of adultolfactorystemcellswiththeaim elusive. Ourgroupstudiesthebasicbiology that gives risetotheseneuralstemcellsremains cell typewithintheolfactoryneuroepithelium and non-neuronalcells.The identityofthe of cellsthatareabletogrow intoneuronal These structuresarethree-dimensionalaggregates laboratory intheformofolfactoryneurospheres. (situated inthenose)andgrown inthe from theadultolfactoryneuroepithelium Neural stemcellscanbeisolated Group leader: Adult StemCells For additionalcontributorspleaseseepages54-55 J.O. andJ.R.Wicking Trust Hillcrest Foundation Henry RothCharitableFoundation (Holocaust) Gallinus PtyLtd Foundation forPrader-Willi Research Clive andVera RamaciottiFoundation BHP BillitonCommunityProgram Australian DeafnessResearchFoundation Amadeus EnergyPtyLtd Alma HazelEddyTrust from thefollowing organisations: The NeuroscienceResearchProgramisgratefulforsupport FUNDING ProfessorJohnShine ProfessorHerbertHerzog

St Vincent’s ClinicFoundation Sanofi-Aventis Australian RotaryHealthResearchFund,District9650 Pfizer GlobalResearchandDevelopment Perpetual/Baxter CharitableFoundation National HealthandMedicalResearchCouncil NSW MinistryforScienceandMedicalResearch Motor NeuroneDiseaseResearchInstitute Lady MaryFairfax Foundation Lang Walker viatheCurranFoundation using electrophysiologicalrecordingtechniques. and we aretestingifthesecellsfunctional turn olfactorystemcellsintohearing(hair) hearing loss.We have shown itispossibleto to replacethecellslostfrominnerearrepairing Our researchaimstouseadultstemcells Group leader: Hearing profoundly impactpeoplewithbraindiseases. to findnovel stemcelltreatmentsthatwill cells, isineffective intheseconditions.We hope own repairsystems,i.e.theformationofnew nerve we work tounderstandwhythenervous system’s to thesemovement andmemorydisorders signalling atnerve celljunctionscontributes of thenervous system.We studyhow abnormal and theirconnectionsfromspecificregions all ofwhichresultfromlossnerve cells spinal cordinjuryandAlzheimer’s disease, neural plasticity)tohelptreatParkinson’s disease, nerve cell’s connections(i.e.how we can harness harness thebrain’s own stemcellsand/ormodulate Our ultimategoalistounderstandhow we can Group leader: Repair &Regeneration Neurodegenerative Disorders – result infunctionalrecovery ofhearing. hearing testswilldetermineifthetransplants cells intotheinnerearofdeafmice.Specialised Microsurgery was developed totransplantstem DrSharonOleskevich DrBryceVissel

NEUROSCIENCE Research Program

Holistic approach: impact on body systems they of specific immune cells and how Studying the behaviour valuable Their territory. Research Unit into undiscovered Autoimmunity is taking Garvan’s led to fruitful collaborations inside and outside the Garvan community insights have RESEARCH REPORT // REPORT RESEARCH AUTOIMMUNITY RESEARCH UNIT RESEARCH AUTOIMMUNITY Left to right: Jerome Darakdjian, Tyani Chan, Professor Fabienne Mackay

Highlights Director: Professor Fabienne Mackay

Our Research Our People

Identifying genetic regions containing Fabienne Mackay was promoted Dr Robert Brink was appointed diabetes susceptibility genes that to Conjoint Professor at UNSW NHMRC Senior Research Fellow contribute to the pathogenic action Professor Fabienne Mackay was an Dr Pablo Silveira was an invited of B cells in an animal model of disease. invited keynote speaker at the 2006 speaker at the annual Australasian Performing whole genome expression Australasian Society of Immunology Society of Immunology conference arrays on B cells from diabetic mice (ASI) meeting, Auckland, New Zealand and non-diabetic mice to aid identification Professor Fabienne Mackay was of new genes that may contribute an invited plenary speaker at both to the pathogenic activity of B cells the Gordon conference on chemokines, causing type 1 diabetes Les Aussois, France, and at a Keystone Demonstrating how changing specific Chemokine conference, Utah, USA genes on particular cell populations involved in presenting beta cell proteins to T cells could protect animal models from developing type 1 diabetes Discovering basic mechanisms underlying antibody production and B cell selection Producing gene knockout mice that demonstrate the essential role of the TRAF3 protein in regulating B cell survival HIGHLIGHTS 45

AUTOIMMUNITY Research Unit AUTOIMMUNITY RESEARCH UNIT 46 and Hashimoto’s disease-allofwhichourunitinvestigates. systemic lupuserythematosus(SLE),Sjögren’s syndrome, treatments canbeineffective. Examplesincludetype1diabetes, autoimmunity astheirdefinitive orprobablecauseandmany More thanfortyhumandiseasesaredefinedashaving immune systemmountingaresponseagainstourown body. on morbidityandqualityoflife.They aretheresultofour appear withoutwarning andcanhave seriousconsequences times asmanywomen asmen.Almostallautoimmunediseases people. For someunknown reason,they affectalmostthree Autoimmune diseasesaffectapproximately oneintwenty

and treatingBcellmalignancies. vaccines, controllingautoimmunedisease, we hopetoreveal new strategiesforimproving ourselves. Byunderstandinghow Bcellsfunction structures and prevent antibodyresponsesagainst cells thatdrive antibodyproductionagainstforeign and differentiation;aswell asthemoleculesand pathways thatregulateBcellsurvival,proliferation, us toidentifythespecificgenesandsignalling the body. Ourinvestigations aimtoenable B cellsproducerogueantibodiesthatattack gravis andhemolyticanemiacanarisewhen Autoimmune diseases suchaslupus,myasthenia Emeritus Professor: Group Leader: B CellImmunobiology of NPYreleaseanditseffectonimmunecells. a betterunderstandingofthecircumstances system continuestowork towards building stress, neuropeptideY(NPY),andtheimmune Our collaborative researchonthelinkbetween in otherconditionsitappearstobeprotective. to drive autoimmunedisordersandwhy oversupply ofBAFF corruptsimmunedefences healthy tissue.We want toknow how the live longerthanthey shouldandcandamage When thereistoomuchBAFF, harmfulBcells and how immuneresponsesareaffectedbystress. our work ontheBcellactivatingfactor(BAFF) - in autoimmunediseases-uncovered from the unappreciatedroleofBlymphocytes We have two principalareasofstudy: Group Leader: Autoimmune Disease Mechanisms For additionalcontributorspleaseseepages54-55 St Vincent’s ClinicFoundation Rebecca Cooperfoundation National HealthandMedicalResearchCouncil Dana Foundation from thefollowing organisations: The Autoimmunity ResearchUnitisgratefulforsupport FUNDING ProfessorFabienne Mackay DrRobertBrink AntonyBasten

that recognisebetacellproteinstopersistand the faultymechanismsthatallow theBcells diabetes (T1D).Ourresearchaimstoidentify cells ofthepancreas,whichleadstotype1 system attackingtheinsulinproducingbeta Our ultimategoalistoprevent theimmune Group Leader: B CellTolerance &Autoimmunity stage therapiesinT1Dsusceptiblehumans. findings thatcouldformthebasisfornew early and functionofthisaberrantpopulationBcells, to identifynovel genesthatcontrolthegeneration thus activatethedestructive Tcells.We alsoaim

DrPablo Silviera

AUTOIMMUNITY Research Unit 48

RESEARCH UNIT REPORT // REPORT UNIT RESEARCH hormones: Performing pituitary gland produces a range of hormones, the levels The understand their role of which determine health or harm. To and Williamson Dave like rely on volunteers in our bodies, we John Dobie to participate in our clinical research PITUITARY RESEARCH UNIT RESEARCH PITUITARY Left to right: Angela Peris, Dave Williamson, Professor Ken Ho, John Dobie

Highlights Director: Professor Ken Ho

Our Work Our People

Showing that hormones control lean Heather Lee, PhD student, Dr Anne Nelson was an body mass by varying how much protein was awarded a Rising Star invited speaker at an International is oxidised for energy production Postgraduate Award and the Symposium on the Use and Harvey Carey Memorial Scholarship Abuse of Growth Hormone, Kobe Discovering that growth hormone from the University of NSW prevents cortisone-induced protein loss Dr Anne Nelson participated Dr Udo Meinhardt received in a strategic planning meeting Finding synthetic oestrogen compounds the Poster Prize at the 3rd of the US Anti-Doping and World called SERMs enhance the action International GH IGF Symposium, Kobe Anti-Doping Agencies in Austin, of growth hormone in certain tissues Texas, to critically review GH tests Professor Ken Ho was invited Completing a major study in over by the Journal of Endocrinology 100 recreational athletes that will to write a speculatory commentary help the design of a test for growth on Endocrinology covering the hormone doping next 60 years to commemorate the founding of the Society for Endocrinology, UK, 60 years ago

HIGHLIGHTS 49

PITUITARY Research Unit PITUITARY Research Unit 50 body fat,muscleandbonemass. understanding how sex hormonesinteractwithgrowth factorstocontrol in adults.Amajorfocusisthephysiologyofgrowth hormones,inparticular children toinfertility, mooddisorders,musclewasting, obesityanddiabetes active pituitaryglandcanleadtoarangeofdiseasesfromdwarfism in strength, appetite,metabolism,moodandreproduction.Anover orunder The pituitaryglandproduceskey hormonesthatcontrolbodygrowth,

of thesemusclegenes. the physiologicalsignificanceofGHregulation and continuetoconductstudiesinvestigate muscle andidentifiednew GH-regulatedgenes on fueloxidation andproteinmetabolisminskeletal we have previously uncovered new effectsofGH in aselective, tissue-specific way. Inaddition, studying thepotentialuseofthesedrugs of SERMsvaryindifferenttissues,thuswe are that arisebecauseofGHimbalances.The effects use oftheseagentsinthetreatmentdiseases basis fordeveloping saferandmoreeffective of GHactionsowe canprovide themolecular the cellularmechanismsforsex steroidregulation Our majoraimwiththisprojectistodissect Project leader: Growth HormoneSignalling conditions suchaskidney failureandmajortrauma. (alone ortogether)totreatprotein-wasting and metabolicactionofGH,canbeused testosterone, whichstrengthensthesecretion We alsowant toknow whetherGHand metabolism, compositionandphysicalfunction. compounds, we arestudyingtheirimpactonbody Given thewidespreadandlongtermuseofthese a numberofdifferentialeffectswithinthebody. action, forexample tamoxifen, arelikely toimpart medicines calledSERMsthatmodulateoestrogen’s that regulatesovary andtestesdevelopment), GH andsecretionofgonadotrophin(ahormone composition inadults.Asoestrogensregulate Growth hormone (GH)isamajorregulatorofbody Project leader: Composition Hormones, MetabolismandBody For additionalcontributorspleaseseepages54-55 World Anti-DopingAgency National HealthandMedicalResearchCouncil InformationTechnology andtheArts Anti-Doping ResearchProgramoftheAustralian Government DepartmentofCommunications, from thefollowing organisations: The PituitaryResearchUnitisgratefulforsupport FUNDING DrKinLeung ProfessorKen Ho

Our work isfocusedonidentifyingfactors so areliabletestisrequiredtodeteritsabuse. evidence thatGHdopingiswidespread, the useofGHisbanned,thereanecdotal from theGHmadebybodyitself. Although in dopingisindistinguishablebynormalmethods, Testing forGHisdifficultbecausetheused Project leader: Growth HormoneDoping based ongeneexpression profilingofblood. The aimistodevelop agenefingerprinttest novel markers ofGHinperipheralbloodcells. using microarray geneprofilingtoidentify and GHinrecreationalathletes.We arealso the biologicalinteractionsbetween testosterone growth hormonesignal.We areinvestigating isoforms, andonproteinsthatrespondtothe regulating thedifferentformsofGH,called

DrAnneNelson

PITUITARY Research Unit 52

Geoff Moles, Deirdre Blakemore, Geoff Moles, Deirdre Blakemore, Accelerating discoveries: Accelerating Garvan relies upon support provided our to take by donors and volunteers research into the future and to help us with the latest technologies. provide speed and pace of our medical The research is enhanced by their involvement Left to right: (CEO, MLC) Tucker Jones, Steve Lyn GARVAN COMMUNITY GARVAN Garvan Community Chloe Veness-Collins Bill Upton Philip Twigg Julie Simpson Jean Pushong Fred &EvaPerger Bob &JoanNeilson Gemma MacDonald Janice Lee Juliet Kirkpatrick Lynne Jones Lyndie Hemery Kate Ellis Graham Curtis Deirdre Blakemore Nikki Alling Barbara Allan 2006 GarvanVolunteers Mr Ralph&MrsLorraineKeyes Mr TKennedy AM&MrsCKennedy Mrs Virginia Kahlbetzer Mr PieterHHuveneers HIH Insurance Mr &MrsBAGinges George Patterson PtyLimited Mr JamesPatrick Garvan&Family Miss Felicia DGarvan Mr LaurenceSFreedman AM Lady MaryFairfax AC OBE The CurranFoundation Mr CharlesPCurranAC Coca-Cola Amatil The BlundyFamily Australian SecuritiesExchange ASX-Reuters CharityFoundation Australian CancerResearchFoundation Mr JohnArmati Allind PtyLimited 2006 LifeGovernors Mr Ray Williams Westfield HoldingsLtd Mr LaurieSutton Mr RobertStraussMBE Mr Tim &MrsSallySims The RitchieFamily The Petre Foundation Paramor Family Mr KPacker AC Order oftheEasternStarChapterNo.38 Dr GrahamO’Neill National Australia BankLtd MLC Limited The LadyProudFoundation for manymoreyears tocome. year andwe lookforward toworking with them all theirhelpduringthisexciting andproductive We aredeeplygratefultoour volunteers for to helpwithclinicaltrialsandresearchprojects. their professionalandadministrative skills team have alsoassistedGarvanresearchbyusing to therunningofFoundation, thevolunteer As well asmakingatremendouscontribution support andencourageourefforts. working tirelesslybehindthescenestoenhance, of almosttwenty dedicatedvolunteers each At Garvan,we areluckytohave theassistance Garvan Volunteers. know we canrelyonourteamofcommitted countless envelopes forourmailouts–we always staffing anantiques exhibition orstuffing community forGarvan’s publichealth seminars, at agolfday, registeringmembers ofthe Whether it’s runningaputtingcompetition

GARVAN COMMUNITY GARVAN COMMUNITY 54 Garvan Supporters Dr Francis MHooper Mr Mike Hobbs In MemoryofRichardHerbert Mrs JuneHerbert Meredith Hellicar Mr MichaelJHawker E Harris Mrs JeanBHale Mrs SandraGross Sharon Green Mrs CherieGlick John Glennie Mr Berel&MrsAgnesGinges Mr J&MrsAGardener Eric &Tonia Gale Elizabeth Fyffe Mr KTFuller Mr Michael&MrsJoy Foulsham Mr BillFerris &MrsLeaFerris Mr JohnBFairfax AM Mr AlanElder Mr PhilDurney David &JaneDuncan Ms RochelleDizon Mr PDavid Dr BCourtenay & MrsSCourtenay Mrs HelenCallander Mr GeoffBushby Ken &BettyBrown Dr Desmond&RuthBright Mr G&MrsCBradley Mr AdrianBourne Mrs DBonser Mrs Kaye Blaiklock Mrs MarieBeville Armati Family Mr MichaelAhrens Mr RossAdamson Individuals Gifts of$1000andabove

Mr WMorley Geoff &JanMoles Mr &MrsRossandVicki Mitchell Mr &MrsTony &PrunellaMerrett Mrs MabsMelville Mrs Pamela McNamara Mr Peter McGovern Sir IanMcFarlane &MrsDympnaMatthews The HonJohnMatthews Mrs Mavis Malouf Mr David MacRae Mrs AnnMacintosh Ms HelenLynch AM Miss MariaLydaki Mr MichaelLowe Mrs LindaLeupen Mr RobertLeeceAMRFD Mrs MLawn &MaryLatham In MemoryofEdward In MemoryofMichaelIsonLarge Mrs JLarge Mr JohnKoch Mr &MrsBJKirkpatrick Mrs AKirby Mrs ElisabethKinross Mr R&MrsLKeyes Mr TKennedy AM Mr Steve Kennedy Professor Geoffrey Kellerman AO Mrs HelenKeir Mrs Virginia Kahlbetzer Mr GJohnson The HonJusticePJacobson Mr PHuveneers Stanley HuntOAM Mrs LAHudson Mr JKLHooton

Mr &MrsJackLynette Skipper Mr SpencerSimmons Mr RossShute Mr MichaelSharpeAO Mr GraemeSee Mr WScott&MsBArndt Ms Shirley Scott Mrs SRothery Hermina Rich Mr Ron&MrsIrisRheinberger Mr IanPope Ms JoanPoole Rob &AnnPedersen Ian Paul Mr Greg&MrsKerry Paramor Dr GrahamJO’Neill &MrsMarianneO’Dea Mr MichaelO’DeaAM Mr MauriceNewman AC Mr GregoryNathan Mr SMurray Mr SYoung Mrs RobinYabsley Dr StanWright Mr AlanWhitfield Mr BenWebb Ms CWalder John &MeganWade Mr IanVale Miss Audrey Taylor Mr NTait OBE&MrsMTait Miss AlisonMStephen Mr Keith &MrsMargaretSteele Mr David &MrsIsabelSmithers Mr &MrsGSmith Dr CMSmith &RoslynHorin Joseph SkrzynskiAM

Lend LeaseCorporation Laing O’Rourke L.J.Hooker CommercialSunshineCoast KPMG John LambleFoundation John &ConnieKennedy CharitableTrust HSBC BankAustralia Limited Housing Finance of Australia PtyLimited Hawker Britton Group GSA Gresham Partners Limited Goldman SachsJBWere Foundation Gavin Anderson&Company G &CBradley Foundation Freehills Ferris Family Foundation DesignInc Sydney Cystic Fibrosis Charitable GiftFund CSR Limited Creative Madness Craig Mostyn&CoPtyLtd Cox Richardson Connell Wagner Commonwealth Bank Clayton Utz CHAMP PrivateEquity CB RichardEllis Capital Investment GroupPtyLimited CAF Australia Boris LendLease Boral Limited BNP Paribas Blake Dawson Waldron BIS ShrapnelPtyLimited Beerworth &Partners Limited Bain &Company AW Edwards PtyLimited Australian SecuritiesExchange Australian LadiesVariety Association ASX-Reuters CharityFoundation Ancher Mortlock&Woolley Amadeus EnergyLimited AGL Employees CommunityFund AGL Organisations Garvan Supporters Gifts of$1000andabove ResMed Foundation Limited Public Trustee NSW PTW Architects Premier MediaGroup Precision GroupofCompanies Piper Alderman Park Hyatt Hotel Pacific Equity Partners P&O Australia Limited NRMA Motoring&Services NRAHSEC Nettleton Tribe (Partnership) PtyLimited Nestle Australia Ltd MLC Limited Minter Ellison MIA ServicesPtyLimited Maple-Brown Family CharitableFoundation Ltd Mamma LenaFoundation Mallesons StephenJaques Macquarie Portfolio Investments PtyLimited Macquarie BankLimited Young Garvan World Presidents’Organisation Wood Family Foundation Witchery Wilson HTMInvestment Group Whitehead Holdings(WA) PtyLtd Theiss PtyLimited The Rodney &JudithO’NeilFoundation The MandarinClub The LadyProudFoundation The JenourFoundation The HuntFamily Foundation The Freedman Foundation The CurranFoundation The AlanElderTrust Taylor Thompson Whitling (NSW)PtyLtd Suttons MotorsManagement Stockland Sanofi-Aventis Rothschild Australia Limited Robert BirdGroup Rider HuntSydney PtyLtd Rice Daubney 55

GARVAN COMMUNITY GARVAN COMMUNITY 56 Partners fortheFuture Left toRight: have alastingimpact onpeople’s healthacrossgenerations Bequests buildafoundation forGarvan’s future. These gifts Ms Faye Williams Mr LTowers Mrs CynthiaSouthwell Mrs Thelma Shepherd Mr Kevin Richardson Mr GeorgeQuigg Mrs JPye Mrs Lesley Powell Mr Peter Olive Mrs Lilian(Billie)Nelson Mrs AmandaMulry Mr John&MrsMaryMiller Mrs MabsMelville Mrs Pamela McNamara Miss MariaLydaki Mr BobKijurina Mrs Virginia Kahlbetzer Mrs FlorenceJones Miss VJenkins Ms HeatherHindle Dr BroniaHatfield Mr Michael&MrsJoy Foulsham Mr Gabriel&MrsJoanFarago Mr JohnDobies Mr Rodney FDarke Mr GrahamCurtis Ms JacquelineCole Mrs JudithClark Mr MichaelJHorton Ken &BettyBrown Mrs BrendaBristow Mr Alan&MrsAnneBoyle Mr Earle&MrsMarleneBoutwell Mr Peter Binne Mrs MAbercrombie MariaLydaki, Lyndie Hemery, Peter Whitehead (PublicTrustee ofNSW) Bequests Estate oftheLateSKleiner Estate oftheLateGWDrover Estate oftheLateNormaShirley Winton Estate ofthelateMargaretCrossley Estate oftheLateDrsJamesandJosephineRyan Estate oftheLateHarryGriffiths Estate oftheLateGeorgeEdward York Estate oftheLateElspethBatley Estate oftheLateDorothyCaton Estate oftheLateDonalRoss-Smith Estate oftheLateColleenKaye Johnson Estate oftheLateBruceFrederick Andrew

Bequests Board Members

Garvan Institute

Left to Right: Bill Ferris, Mark Wainwright, Martin Hoffman, Graham J Bradley, Nicholas Curtis, Mary Foley, Lisa McIntyre, Greg Paramor

Left to Right: Sister Carol Pedersen, Michael Reid, Warren Scott, John Shine, Peter J Smith Bernadette Tobin, Ronald Trent

Garvan Research Foundation

Left to Right: Graham Bradley, Lauren Adlam, Alec Brennan, Philip Marcus Clark, Melinda Conrad, Bill Ferris, Lyn Gearing

Left to Right: Meredith Hellicar, Byram Johnston, John Koch, Sister Paulina Pilkington, Carole Renouf Russell Scrimshaw, John Shine

Left to Right: Timothy J Sims, Ian Smith, Nick Tait, Peter Wade, Richard Warburton, Marvin Weinman GARVAN INSTITUTE 58 He is also a director of the Garvan Research Foundation. and Australian Pacific Paper ProductsPtyLtd. Resources PtyLtd,Tucker Seabrook(Aust) Limited, United CommunicationsLimited; Director, Bradken Australian Trade Commission(Austrade) andAustar Research. Former directorshipsinclude:Chairman, Services PtyLtdandtheGarvanInstituteofMedical Mr Ferris iscurrentlyChairmanofInternationalEnergy and managementbuyout fundinginAustralasia. groups, providing venture capital,expansion capital Equity Group,oneofAustralia’s leadingprivatecapital Bill Ferris isExecutive ChairmanoftheCHAMPPrivate Nominated by Trustees ofStVincent’s Hospital Chairman Bill Ferris AO Garvan InstituteBoard Director oftheInstitutewhoisappointedbyBoard. the Governor ofNew SouthWales andtheExecutive by Garvan’s variousstakeholders andappointedby meets quarterlyandcomprises15members,nominated delegation ofauthoritytocommittees.Garvan’s Board in theAct.The Boardapproves andsupervisesthe and controltheaffairsofInstituteaslaiddown is empowered undertheActtodeterminepolicy The BoardisGarvan’s governing body, which Structure required toaccomplishitsmission. the Institutewithinfrastructureandservices was completed.This world-class facilityprovides In 1997,Garvan’s new medicalresearchcentre volume andstandardofitsresearchoutputs. and thishasbeenreflectedintheincreasing achieved significantgrowth insizeandfunding in 1992and1998.Duringthe1990s,Garvan NHMRC BlockGrantwas renewed andincreased and Garvanwas the soleNSWrecipient.Garvan’s accorded thisblockfundingstatuswithinAustralia Only sixmedicalresearchinstitutionshave been was awarded aNHMRCCentreBlockGrant. In 1986,afteraninternationalreview, Garvan University ofNSW andStVincent’s Hospital. Garvan today has formalaffiliationswiththe as anautonomous,non-profitresearchinstitute. of MedicalResearchActthatincorporatedGarvan Wales Parliament passedtheGarvanInstitute of StVincent’s Hospital.In1984,theNew South Garvan initiallyfunctionedasadepartment NSW parliamentarianandbusinessleader. after JamesPatrick Garvan(1843-1896),distinguished of theGarvanInstituteMedicalResearch.Itisnamed its CentenaryAppealthatfundedtheestablishment Hospital. Onehundredyears laterthehospitalheld In 1857,theSistersofCharityfoundedStVincent’s History

Managing DirectorofLoopWireless. Priortothat Martin HoffmanisChiefExecutive Officerand Nominated by Sisters ofCharity Treasurer Martin Hoffman and iscurrentlyaDirectorofUniSearchLimited. of anumberCo-operative ResearchCentres the endof2000.Hehasserved ontheboards Faculty ofEngineering,apositionhehelduntil in 1991was appointed DeanofAustralia’s largest he was awarded apersonalChairatUNSWand a DScfromtheUniversity ofSouthAustralia. In1989, a PhDfromMcMasterUniversity inCanadaand Chemical EngineeringfromtheUniversity ofAdelaide, Chemistry andaMasterofAppliedSciencein Wainwright holdsanHonoursDegreeinApplied of New SouthWales on1July2004.Professor Vice-Chancellor andPresidentoftheUniversity Professor MarkWainwright was appointed Nominated by University ofNew South Wales Deputy Chairman Mark Wainwright AM as adirectoroftheSisters Charity HealthService. & MaterHealthSydney inAugust 2004andalsoserves was appointedasChairmanoftheBoardSt Vincent’s public companyspecialising in rareearths.MrCurtis Chairman ofLynas CorporationLimited,anAustralian banking andtheresourcesindustry. HeisExecutive Nicholas Curtishasabackgroundininvestment Nominated by Trustees ofStVincent’s Hospital Nicholas Curtis the GarvanInstituteBoardinNovember 1999. Research Foundation inJune1999andjoined Mr. Bradley was appointedChairmanofGarvan national managingpartnerofBlake Dawson Waldron. Company, managementconsultants,andaformer Australia. Heisaformer partnerofMcKinsey & he was ManagingDirectorofPerpetual Trustees American Australia Limited. From 1995to2003 Limited, HSBCBankAustralia LimitedandAnglo Mr. Bradley isChairmanofStocklandCorporation Graham Bradley isaprofessionalcompanydirector. Nominated by Garvan ResearchFoundation Graham JBradley of theGarvanInstitute. Between 1996and1999MrHoffmanwas COO of seniorroleswithJohnFairfax HoldingsLtd. in February 2003,MartinHoffmanheldanumber Broadcasting Limited(PBL).Beforejoiningninemsn joint venture between MicrosoftandPublishing& he was ChiefExecutive Officerofninemsn,a50:50 (until October, 2006)

Australian PropertyInstitute. Property CouncilofAustralia andisaFellow ofthe a directorofnumbercompanies,includingthe of thePropertyCouncilAustralia. Heiscurrently HeistheimmediatepastPresident January 2005. the acquisitionofJamesFielding Groupin Managing DirectoroftheMirvacGroupfollowing approximately 30years. MrParamor was appointed and propertyfundsmanagementindustryfor Greg Paramor hasbeeninvolved intherealestate Nominated by Garvan ResearchFoundation Greg Paramor Ltd andAtCorMedicalPtyLtd. companies. SheisalsoadirectorofBiotechCapital she advisedmanyoftheworld’s leadingbiotechnology co-heading L.E.K.’s LifeSciencespracticewhere to Sydney in2002afternineyears intheUnitedStates with commercialisinginnovation. DrMcIntyrerelocated clients primarilyfocusingonthechallengesassociated and hasworked withover 80differentbiotechnology 14 years consultingforthebiotechnologysector Asia Pacific LifeSciencespractice.Shehas over consulting firmL.E.K.ConsultingandheadofL.E.K.’s Dr LisaMcIntyreisapartnerwiththestrategy Nominated by Federal Ministerfor Health Lisa McIntyre Precinct andGarvanResearchFoundation. Institute, theStVincent’s Research&Biotechnology a directoroftheVictor ChangCardiacResearch Businesswoman of theYear in1998. Sheisalso University ofWestern Sydney andwas NSWTelstra Ms Foley isamemberoftheBoardTrustees, for Mayne Nickless privatehealthcarebusiness. and seniorexecutive managementpositions and Executive Director, NSWOfficeofHealth Policy Deputy Director-General, NSWDepartmentofHealth and MaterHealthSydney. Previous positionsinclude Mary Foley isChiefExecutive Officer, St Vincent’s Nominated by Sisters ofCharity Mary Foley

Prior tothisappointmenthewas Directorofthe 2004 tillitsabsorptionintoasuperMinistryin2006. for ScienceandMedicalResearchinNSWfrom as DirectorGeneralofthenewly formedMinistry Michael Reid’s mostrecentappointmentwas Nominated by NSW Ministerfor Health Michael Reid consultations forthepoor. West, wheresheprovides probonohomoeopathic Services. SrCarollives andWorks inSydney’s South local levels inthedevelopment ofAlcoholandDrug Committees, andwas active atnational,stateand was amemberof variousHumanResearchEthics Homoeopathic Medicine.For over 20years SrCarol work, obtainingan AssociateDiplomainAdvanced Medicine, andrecentlycompletedpostgraduate Diploma fromtheSydney CollegeofHomoeopathic from thesameinstitution.ShealsoholdsanAdvanced She holdsaPhDfromUNSWandBSW(Hons1) Vincent’s Sydney in1963andisaSisterofCharity. Carol Pedersen graduatedasatrainednurseatSt Nominated by the Sisters ofCharity Sister CarolPedersen RSC and asa lawyer inNew York andCalifornia. Warren isadmittedasasolicitorinNew SouthWales Bar AssociationandtheCaliforniaAssociation. Wales, theAmericanBarAssociation,New York Leadership Dialogue,theLaw SocietyofNew South as well asadelegatetotheAustralian American Chairman, Woolcock InstituteofMedical Research, Counsel andManagingDirectorinAustralia. Heis Warren Scottisadirectorof CitigroupandGeneral Nominated by NSWMinisterfor Health Warren Scott including mentoringindividualsandorganisations. and academiccontractsbothinAustralia andoverseas, and iscurrentlyengagedinavarietyofhealth,science recently hehasre-establishedhisconsultingcompany position ofDirectorGeneralNSWHealth.Most Sydney. For thefive years priortothisheheldthe of PublicAdministrationattheUniversity ofWestern of MedicineattheUniversity ofSydney andtheFaculty He holdsAdjunctProfessorshipsintheFaculty for InternationalHealth,University ofSydney. Policy andPracticeProgramattheGeorgeInstitute

GOVERNANCE GOVERNANCE 60 Mater Health,POWMRIandNEWSOUTHInnovations. currently adirectorontheboardsofStVincent’s and in Australia andNew Zealand.Professor Smithis He hasserved asdirectoronanumberofboards Universities ofQueensland,MelbourneandAuckland. Melbourne andsenioracademicappointmentsatthe senior hospitalmanagementpostsinBrisbaneand further studyintheUSAandGermany. Hehasheld in paediatriconcologyandcancerresearchfollowing of theUniversity of Queenslandandspecialised University ofNew SouthWales. Heisagraduate Professor SmithisDean,Faculty ofMedicine, Nominated by University ofNSW Peter JSmith Engineering &Innovation Council(PMSEIC). is alsoamemberofthePrimeMinister’s Science, Research Council(NHMRC).ProfessorShine ex-Chairman ofthe NationalHealthandMedical bodies throughoutAustralia, includingtherecent and aDirectorofmanyscientific,researchmedical and ProfessorofMedicineattheUniversity ofNSW, Foundation. HeisProfessorofMolecular Biology and aboardmemberoftheGarvanResearch of theGarvanInstituteMedicalResearch Professor JohnShineisExecutive Director Appointed by Garvan InstituteBoard John ShineAO FAA

as well asamemberoftheNHMRCCouncil. of theNHMRCHumanGeneticsAdvisoryCommittee Research Committeesince1997andisChairman Hospital. HehasbeenamemberoftheNHMRC of MolecularandClinicalGenetics,Royal PrinceAlfred University ofSydney andHeadoftheDepartment Ronald Trent isProfessorofMolecularGenetics, Nominated by Federal Ministerfor Health Ronald Trent Health andAgedCareServicesinAustralia. which preparedthefirstCodeofEthicsforCatholic of theNHMRC.Shealsochaireddraftinggroup Health EthicsCommittee,aprincipalcommittee Wales. Sheserved forthreetrienniaontheAustralian School ofMedicineattheUniversity ofNew South of Sydney, andConjointAssociateProfessorinthe Professor intheFaculty ofMedicineattheUniversity Children’s HospitalatWestmead, HonoraryAssociate University. DrTobin isHonoraryEthicistatthe and ReaderinPhilosophyatAustralian Catholic Centre forEthicsatStVincent’s Hospital,Sydney, A/Professor BernadetteTobin isDirectorofthePlunkett Nominated by Trustees ofStVincent’s Hospital Bernadette Tobin

He joinedtheBoardin2005. Limited, DJClarkPtyLtd,and StJamesEthicsCentre. of INGManagementLtd,CRIAsset of theJPMorganAdvisoryCouncilandadirector industries andintheretailsector. MrClark isamember roles withinthepetroleumandindustrialpackaging and CEO.Hehasalsoheldavarietyofmanagement and MallesonsStephenJaquesasManagingPartner of Australia’s two largestlaw firms,MinterEllison has ledthesuccessfulgrowth anddevelopment Originally trainedinlaw andmanagement,MrClark Philip MarcusClark joined theFoundation Boardin2000. of theSenateSydney University. MrBrennan a directorofEmecoLimited,andFellow today. HeisalsoChairmanofGove AluminiumLtd, the corporateculturethatdrives thecompany of thecompany’s way ofthinkinganddoingbusiness- He hasplayed animportantroleintheshaping diversified businessesthatnow make upCSR. in seniormanagement,includingrunningthe with CSR.Hislast25years have beenspent of CSRLimited.MrBrennanhasserved 37years Alec BrennanisCEOandManagingDirector Alec Brennan Ex-Officio Lauren Adlam,Young GarvanChair, the GarvanInstituteBoardinNovember 1999. Research Foundation inJune1999andjoined Mr. Bradley was appointedChairmanofGarvan national managingpartnerofBlake Dawson Waldron. Company, managementconsultants,andaformer Australia. HeisaformerpartnerofMcKinsey & he was Managing DirectorofPerpetual Trustees American Australia Limited.From 1995 to2003 Limited, HSBCBankAustralia LimitedandAnglo Mr. Bradley isChairmanofStocklandCorporation Graham Bradley is aprofessionalcompanydirector. Graham JBradley (Chairman) ultimate directionoftheGarvanInstituteBoard. policy andcontrolofaffairssubjecttothe governing bodytodeterminetheFoundation’s The Foundation’s Boardisempowered asthe become Garvan’s marketing andfundraisingarm. Over theyears, theFoundation hasevolved to financial supportfromcompaniesandindividuals. an additionalsourceofresearchfundsbyattracting in 1981toprovide theGarvanInstitutewith Garvan ResearchFoundation was established Garvan Research Foundation Board

and Australian Pacific Paper ProductsPtyLtd. Resources PtyLtd,Tucker Seabrook(Aust) Limited, United CommunicationsLimited;Director, Bradken Australian Trade Commission(Austrade) andAustar Research. Former directorshipsinclude: Chairman, Services PtyLtdandtheGarvanInstituteofMedical Mr Ferris iscurrentlyChairmanofInternational Energy and managementbuyout fundinginAustralasia. groups, providing venture capital,expansion capital Equity Group,oneofAustralia’s leadingprivatecapital Bill Ferris isExecutive ChairmanoftheCHAMPPrivate Bill Ferris AO joined theFoundation BoardinSeptember 2003. chapter, andtheHarvardClubofAustralia. MsConrad include Young EntrepreneursOrganisation-Sydney Colgate-Palmolive. Voluntary boardmemberships management rolesatHarvardBusinessSchooland Prior toherestablishmentofConrads,sheheld Founder oftheretailstorechain,Conrads Warehouse. Melinda ConradisformerManagingDirectorand Melinda Conrad Ms HellicarjoinedtheFoundation BoardinMarch2002. and ManagingDirectorofTNTLogisticsAsia. Chief Executive OfficerofCorrsChambers Westgarth Managing DirectorofInTech Financial Services, Leadership. Herformerexecutive rolesinclude and was awarded aCentenaryMedalforBusiness Holdings. MeredithisamemberoftheTakeovers Panel Life), SouthernCrossAirportsGroup,andAmalgamated Institute; andadirectorofAMP(andChairman Hardie Industries,HLAEnvirosciences,andtheSydney in strategyandchange.SheisChairmanofJames Meredith Hellicarisacompanydirectorandconsultant Meredith Hellicar corporate financeandmanagementconsulting. experience insuperannuation,fundsmanagement, from 1997to2002,andhasover 30years business Executive oftheNSWStateSuperannuationschemes not forprofitorganisations.MsGearing was theChief Australia PtyLimited andIMBLimitedtwo other Corporation Limited,HancockNaturalResourcesGroup of Charity. MsGearing isaDirectorofStockland asarepresentative oftheSisters board in2005 Lyn Gearingwas appointedtotheGarvanFoundation Lyn Gearing

FOUNDATION GOVERNANCE GOVERNANCE 62 the Foundation Boardin2000. and internationalresponsibilities.MrKoch joined Commonwealth Bankassumingarangeofdomestic young adults.Hehada32year careerwiththe Foundation whichassistsintellectuallydisabled Finance Committee. HeisChair, Woods Cottage member ofStVincent’s HospitalandChairofits based Forma GroupofCompanies,aformerboard John Koch isChiefRepresentative oftheHongKong John Koch Board in2005. Banking department.MrKingjoinedtheFoundation Consumer andIndustrialdivisionsoftheInvestment as Executive DirectorandCo-HeadoftheHealthcare, and LondonofficesbeforereturningtoSydney in2001 1994. HefulfilledseniorrolesinboththeNew York equity salesandresearchwas madeaPartner in numerous productlinesincludinginvestment banking, and GoldmanSachsJBWere. Hehasworked across investment banking andfinancialadvicewithJBWere Ross Kinghasspentthelast15years providing Ross King companies. HejoinedtheFoundation Board in1997. experience. Heserves ontheboardofanumber He hasover 30years managementconsulting processing servicestoanumberofindustrysectors. MainstreamBPO, acompanyproviding backoffice Byram JohnstonistheChiefExecutive Officerof Byram JohnstonOAM

for theFaculty ofScience atUNSW. she was DirectorofMarketing andDevelopment as DirectoroftheGarvanResearchFoundation, at WWFAustralia. Justpriortotakingupherposition years asDirector ofFundraisingandCommunications and mediaspokesperson. Shethenspentfour as aseniorpolicyofficer, consumeradvocate years attheAustralian Consumers’Association print andaudio-visualresources.Carolespenteight Health andsettingupherown businessproducing of healthandeducation,includingastintatNSW of Management.Initially, Caroleworked inthefields in managementattheAustralian GraduateSchool fundraising professional,whohasalsotrained sector. Sheisamarketing, communicationsand Carole Renoufhasbuilthercareerinthenot-for-profit Carole Renouf since 1994. and hasbeenamemberoftheFoundation Board from theGarvanInstituteBoardinFebruary 2000 Federal DepartmentofHealth.SisterPaulina resigned and AssistantDirectorGeneral,NursingBranch, and HealthServicesCommission(SaxCommission) formation, having beenamemberoftheHospitals Sister Paulina hasabroadbackgroundinhealthpolicy Sister Paulina PilkingtonRSCAM joined theFoundation Boardin2000. Telecom New ZealandAustralia. MrScrimshaw and DirectoroftheBoardsEDSAustralia and also heldthepositionsofChairman,Cyberlynx In hisroleattheCommonwealth Bank,MrScrimshaw with OptusCommunications,AmdahlandIBM. business operationsandseniormanagementpositions Unit. Hehasalsopreviously heldexecutive marketing, Technology, OperationsandProcurement Business the GroupExecutive oftheCommonwealth Bank’s Metals GroupLimited.Hewas, untillate2002, Russell Scrimshaw isaboardmemberofFortescue Russell Scrimshaw

Board in2000. for BritishAirways. MrTait joinedtheFoundation General ManagerInvestments andJointVentures and ConcordeInternationalTravel andwas previously of QantasAirways, BritishAirways Holdings(Australia) and anamateurgrazier. Heisaformerdirector Nick Tait isadirectorofGreenGlobeAsiaPacific Nick Tait OBEFAICD and theStateLibraryofNew SouthWales. groups includingtheWhitney MuseuminNew York on anumberofgovernment andphilanthropicadvisory major markets aroundtheworld. MrSmithhasserved e-business consultancy, whichnow operatesinmost PLC. Healsoledthedevelopment ofCordiant’s global director ofthepubliclylistedCordiantCommunications as PresidentInternationalofBatesWorldwide and Group in2003,MrSmithspentfive years inNew York the managementbuyout ofThe Communications communications andmediaindustries.Priortoleading director andadvisorintheadvertising, marketing He hasmorethan20years experience asacompany Ian SmithiscurrentlyChiefExecutive ofYahoo!7. Ian Smith the Foundation Boardin1994. of theRavenswood SchoolforGirls.MrSimsjoined Australian CharitiesFundandaMemberoftheBoard of thefirm.Heisadirectorandfounder Partner ofLEKPartnership AsiaPacific andafounder Partner atBainInternationalandbeforethatManaging companies. Hewas previously ChairmanandManaging Partners. HeisaDirectorofnumberportfolio Tim SimsisManagingDirectoratPacific Equity Timothy JSims Council (PMSEIC). Prime Minister’s Science,Engineering&Innovation (NHMRC). ProfessorShineisalsoamemberofthe of theNationalHealthandMedicalResearchCouncil throughout Australia, includingtherecentex-Chairman of manyscientific,researchandmedicalbodies of MedicineattheUniversity ofNSW, andaDirector He isProfessorofMolecularBiologyand member oftheGarvanResearchFoundation. Garvan InstituteofMedicalResearchandaboard Professor JohnShineisExecutive Directorofthe John ShineAO FAA

adviser. HeisadirectorofCoSportPtyLtdand Marvin Weinman isacompanydirectorandbusiness Marvin Weinman Mr Warburton joinedtheFoundation Boardin1999. Zealand, whomhehasworked withfor30years. Chairman andCEOofDuPont Australia andNew boards withinAustralia. MrWarburton isaformer various otherpositionsoncommitteesandadvisory Printing Australia, CitibankandNufarm.Heholds Fund, andTandou Limited.HeisadirectorofNote Australia, theBoardofTaxation, MagellanFlagship Dick Warburton iscurrentlyChairmanofCaltex Richard FE(Dick)Warburton AO and HeadofitsGlobalAustralian Equitiesbusiness. and atJPMorganhewas ManagingDirector held variousseniorrolesatJBWere untilitsmerger returning toAustralia. OnhisreturnMrWade 15 years inEurope andtheUnitedStatesbefore recently hewas with JPMorgan.Heworked fornearly and itscurrentform,GoldmanSachsJBWere; more investment banking andfinancialadvicewithJBWere director. Peter previously spentover 25years providing Mr Wade iscurrentlyaprivateinvestor andcompany Peter Wade Mr Weinman joinedtheFoundation Boardin2003. of theIntensive CareFoundation ofAustralia. He isalsoamemberoftheCorporateCommittee of OutcomesAustralia andShareLifeAustralia. to Garvan,hiscommunityinterestsincludeChairman roles atBTRNylex LtdandACI Ltd. In addition and BoralBuildingProducts,seniormanagement include ManagingDirector, GeorgeWeston Foods Proplanet PtyLtd.Hisprevious executive positions

FOUNDATION GOVERNANCE Publications

1. Allison SJ, Baldock P, Sainsbury A, Enriquez R, 12. Bliuc D, Eisman JA, Center JR. A randomized Lee NJ, Lin EJ, Klugman M, During M, Eisman JA, study of two different information-based Li M, Pan LC, Herzog H, Gardiner EM. Conditional interventions on the management of osteoporosis deletion of hypothalamic Y2 receptors reverts in minimal and moderate trauma fractures. gonadectomy-induced bone loss in adult mice. Osteoporos Int 2006; 17(9):1309-17. J Biol Chem 2006; 281(33):23436-44. 13. Boey D, Heibronn L, Sainsbury A, Laybutt R, 2. Allison SJ, Herzog H. NPY and bone. Exs 2006; Kriketos A, Herzog H, Campbell LV. Low serum PYY (95):171-82. is linked to insulin resistance in first-degree relatives of subjects with type 2 diabetes. Neuropeptide 3. Arsov T, Silva DG, O’Bryan MK, Sainsbury A, 2006; 40(5):317-24. Lee NJ, Kennedy C, Manji SS, Nelms K, Liu C, Vinuesa CG, de Kretser DM, Goodnow CC, 14. Boey D, Herzog H. PYY and regulation of Petrovsky N. Fat aussie--a new Alstrom syndrome energy homeostasis. In: Ho K, Chihara K, editors. mouse showing a critical role for ALMS1 in obesity, HypoCCS Series - Molecular pathogenesis and diabetes, and spermatogenesis. Mol Endocrinol therapy of pituitary disease; 2006. p. 85-101. 2006; 20(7):1610-22. 15. Boey D, Lin S, Karl T, Baldock P, Lee N, Enriquez 4. Baheiraei A, Ritchie JE, Eisman JA, Nguyen R, Couzens M, Slack K, Dallmann R, Sainsbury A, TV. Exploring factors influencing osteoporosis Herzog H. Peptide YY ablation in mice leads to the prevention and control: a qualitative study development of hyperinsulinaemia and obesity. of Iranian men and women in Australia. Maturitas Diabetologia 2006; 49(6):1360-70. 2006; 54(2):127-34. 16. Boyman O, Cho JH, Tan JT, Surh CD, Sprent 5. Balasubramaniam A, Mullins DE, Lin S, Zhai W, J. A major histocompatibility complex class I- Tao Z, Dhawan VC, Guzzi M, Knittel JJ, Slack K, dependent subset of memory phenotype CD8+ Herzog H, Parker EM. Neuropeptide Y (NPY) Y4 cells. J Exp Med 2006; 203(7):1817-25. receptor selective agonists based on NPY (32-36): 17. Boyman O, Kovar M, Rubinstein MP, Surh CD, development of an anorectic Y4 receptor selective Sprent J. Selective stimulation of T cell subsets agonist with picomolar affinity.Journal of Medicinal with antibody-cytokine immune complexes. Chemistry 2006; 49(8):2661-5. Science 2006; 311(5769):1924-7. 6. Baldock PA, Allison S, McDonald MM, Sainsbury 18. Brink R. Regulation of B cell self-tolerance A, Enriquez RF, Little DG, Eisman JA, Gardiner EM, by BAFF. Sem Immunol 2006; 18:276-283. Herzog H. Hypothalamic regulation of cortical bone mass: opposing activity of Y2 receptor and leptin 19. Brink R, Basten A. B cell self tolerance. In: Rose pathways. J Bone Miner Res 2006; 21(10):1600-7. N, Mackay I, editors. The Autoimmune Diseases: Elsevier Science Ltd (USA). 2006. p. 167-177. 7. Baldock PA, Thomas GP, Hodge JM, Baker SU, Dressel U, O’Loughlin PD, Nicholson GC, Briffa KH, 20. Brummer T, Martin P, Herzog S, Misawa Eisman JA, Gardiner EM. Vitamin D action Y, Daly RJ, Reth M. Functional analysis of the 64 and regulation of bone remodeling: suppression regulatory requirements of B-Raf and the B-RafV600E of osteoclastogenesis by the mature osteoblast. oncoprotein. Oncogene 2006; 25:6262-6276. J Bone Miner Res 2006; 21(10):1618-26. 21. Brummer T, Schramek D, Hayes VM, Bennett 8. Barnett MH, Sutton I. The pathology of multiple HL, Caldon CE, Musgrove EA, Daly RJ. Increased sclerosis: a paradigm shift. Curr Opin Neurol 2006; proliferation and altered growth factor dependence 19(3):242-7. of human mammary epithelial cells overexpressing the Gab2 docking protein. J Biol Chem 2006; 9. Batterham RL, Heffron H, Kapoor S, Chivers JE, 281(1):626-637. Chandarana K, Herzog H, Le Roux CW, Thomas EL, Bell JD, Withers DJ. Critical role for peptide 22. Bryant W, Greenfield JR, Chisholm DJ, YY in protein-mediated satiation and body-weight Campbell LV. Diabetes guidelines: easier to preach regulation. Cell Metab 2006; 4(3):223-33. than to practise? Med J Aust 2006; 185:305-9. 10. Bennett HL, Daly RJ. Functional Characterization 23. Burt MG, Gibney J, Ho KK. Characterization of PIK3CA as a breast cancer oncogene. of the metabolic phenotypes of Cushing’s In: Breast Cancer Online (BCO) www.bco.org; 2006. syndrome and growth hormone deficiency: a study p. Published. of body composition and energy metabolism. Clin Endocrinol (Oxf) 2006; 64(4):436-43. 11. Blair IP, Chetcuti AF, Badenhop RF, Scimone A, Moses MJ, Adams LJ, Craddock N, Green E, Kirov 24. Burt MG, Ho KK. Newer options in the G, Owen MJ, Kwok JB, Donald JA, Mitchell PB, management of acromegaly. Intern Med J 2006; Schofield PR. Positional cloning, association analysis 36(7):437-44. and expression studies provide convergent evidence 25. Butt AJ. Review of: Bone marrow stromal that the cadherin gene FAT contains a bipolar cell-derived growth inhibitor inhibits growth and disorder susceptibility allele. Mol Psychiatry 2006; migration of breast cancer cells via induction of cell 11(4):372-83. cycle arrest and apoptosis. In: Breast Cancer Online (BCO) www.bco.org; 2006. p. Published. J Endocrinol in whitebutnot inredmuscle. intracellular partitioningoffatty acidtoward storage SM. Oraladministrationofglucose promotes JB, DaugaardJR,IglesiasMA, KraegenEW, Furler 39. B cells. prone BAFF transgenicmicelackingmarginalzone of nephritisbutnotsialadenitisinautoimmune- ML, NgLG,GommermanJ,Mackay F. Development 38. Res 37. disease. New territoryaheadforgeneticsandchromosomal 36. 2006; 117(6):1477-83. and nonallergicindividuals. AM. AntigenselectionintheIgEresponseofallergic 35. J BiolChem affinity ligandfortheendocytosisreceptorLRP. The urokinase/PAI-2 complex: anew high 34. 191:415-25. delays hairregrowth inmice. Blazek K,Wilkins RJ,Pearson AJ.Prolactin 33. Int JNeuropsychopharmacol the moodstabilizersodiumvalproate. PR. Alteredgeneexpression inmicetreatedwith 32. IUBMB Life phospholipase Dandphosphatidicacid. Hughes WE.Phospholipidsignallingthrough 31. knockout mice. Emotional behavior in aged neuropeptide Y (NPY) Y2 30. 55:2688-2697. via AMP-Activated ProteinKinase. Glucose Uptake and Fatty AcidOxidationInVitro Insulin-Stimulated GlucoseDisposalinHumansand Pedersen BK,Febbraio MA.Interleukin-6Increases Behrens C,Watt MG,JamesDE,Kemp BE, WG, HolmesAG, RammG,Prelovsek O,Hohnen- 29 that iswhatexperience means. 28. Biochem EA. Cellcyclecontrolinbreastcancercells. 27. 2006; 5(9):2300-2309. in humanbreastcancercells. mammary gland,inducesBim-dependentapoptosis A novel planttoxin, persin,withinvivo activityinthe TJ, LehrbachGM,Watts CK,SutherlandRL. MacLeod JK,Liaw TYE,Kavallaris M,Somers-Edgar 26. Garvan Institute Publications 2006 . Carey AL,Steinberg GR,Macaulay SL,Thomas Craven AJ,Nixon AJ,AshbyMG,OrmandyCJ, Fosgerau K, Fledelius C, Pedersen KE, Kristensen FletcherCA, SutherlandAP, GroomJR,Batten EismanJA.Ethicsinpublications. DuncanC.Lookingbeyond themicroscope: Dahlke I,NottDJ,RuhnoJ,Sewell WA, Collins CroucherD,SaundersDN,RansonM. ChetcutiA,AdamsLJ,MitchellPB,Schofield CazzolliR,ShemonAN,Fang MQ, CarvajalC,DumontY, HerzogH,QuirionR. CampbellLV. Ourpatientsremainwithus: CaldonCE,DalyRJ,SutherlandRL,Musgrove ButtAJ,RobertsCG,Seawright AA,OelrichsPB, 2006;21:1-3. Eur JImmunol Australian Medicine 2006;97:261-274. 2006;58(8):457-61. 2006;281(15):10206-10213. 2006;190:651-8. J MolNeurosci 2006; 36(9):2504-14. J AllergyClinImmunol 2006;(June):18. J Endocrinol 2006;9(3):267-76. Mol CancerTher

2006;28(3):239-45. Lancet Diabetes

J BoneMiner 2006:367.

2006;

2006; J Cell

pituitary functioninthefatiguedpatient: areview 45. 2:195-211 2 diabetes:causeandeffect? between ‘inflammation’, insulinresistanceandtype 44. oscillator. in themurinemutantsspastic,spasmodic,and underlie alteredglycinergicsynaptictransmission Callister RJ.Distinctphysiologicalmechanisms 43. with IL-21. of proliferative responses following stimulation of humanBcellbehavior andamplification 42. Spring) independent oflipidavailability. of adiponectinwithinsulinsensitivityinhumans, Campbell LV, Kriketos AD.Relationship 41. Nat Genet supression acrossanentirechromosomeband. in colorectalcancerresultscoordinategene RA, Peinado MA,ClarkSJ.Epigeneticremodeling 40. 15(6):1223-1225. survival. 1 H6Dpolymorphism,prostatecancerrisk,and Sutherland RL.Macrophageinhibitorycytokine- Padilla EJD,English DR,HopperJL,GilesGG, 51. Mol Endocrinol prolactin-induced mammaryglanddevelopment. Visvader JE,OrmandyCJ.Socs2andElf5mediate Hilton HN,Wittlin S,Alexander WS,LindemanGJ, Naylor MJ, Robertson FG, Blazek KD, Kazlauskas M, 50. J Appl Physiol regulation withintenseexercise inType 1diabetes. Effects ofsprinttrainingonextrarenal potassium DJ, HunterSK,Thom JM,MorrisNR,FlackJR. 49. Proc NatlAcadSciUSA exchange factorandparticipatesinTcellactivation. product SAPassociateswithPAK-interacting The X-linked lymphoproliferative diseasegene 48. Neurobiol Aging atrophy ingeneticformsofAlzheimer’s disease. Halliday GM.Differencesinregionalbrain 47. Thorax of HPA axisinadultstakinginhaledcorticosteroids. 46. of 59cases. GrahamBA, SchofieldPR,Sah P, MargrieTW, GreenfieldJR,SamarasK.Evaluationof GreenfieldJR,Campbell LV. Relationship GoodKL,Bryant VL,Tangye SG.Kinetics FurlerSM,GanSK,Poynten AM,ChisholmDJ, Frigola J,SongStirzaker C,Hinshelwood Hayes VM,Severi G,Southey MC, HarrisJ,StanfordPM,SutherlandK,Oakes SR, HarmerAR,RuellPA, McKenna MJ,Chisholm GuC,Tangye SG,SunX,LuoY, LinZ,Wu J. GregoryGC,MacdonaldV, SchofieldPR,KrilJJ, GreenfieldJR,SamarasK.Suppression 2006;61(3):272-3. 2006;14(2):228-34. Cancer EpidemiolBiomarkPrev J Neurosci 2006;38(5):540-549. J Immunol Eur J Endocrinol 2006;100(1):26-34. 2006;20(5):1177-1187. 2006;27(3):387-93. 2006;26(18):4880-90. 2006;177(8):5236-47. 2006;103(39):14447-52. 2006; 154(1):147-157. Curr DiabRev Obesity (Silver

2006;

PUBLICATIONS Publications

52. Heilbronn LK, de Jonge L, Frisard MI, DeLany 63. Kovar M, Boyman O, Shen X, Hwang I, JP, Larson-Meyer DE, Rood J, Nguyen T, Martin CK, Kohler R, Sprent J. Direct stimulation of T cells by Volaufova J, Most MM, Greenway FL, Smith SR, membrane vesicles from antigen-presenting cells. Deutsch WA, Williamson DA, Ravussin E. Effect Proc Natl Acad Sci U S A 2006; 103(31):11671-6. of 6-month calorie restriction on biomarkers of 64. Kraegen EW, Saha AK, Preston E, Wilks D, longevity, metabolic adaptation, and oxidative stress Hoy AJ, Cooney GJ, Ruderman NB. Increased in overweight individuals: a randomized controlled malonyl-CoA and diacylglycerol content and trial. Jama 2006; 295(13):1539-48. reduced AMPK activity accompany insulin 53. Heinzelmann-Schwarz VA, Gardiner-Garden M, resistance induced by glucose infusion in muscle Henshall SM, Scurry JP, Scolyer RA, Smith AN, and liver of rats. Am J Physiol Endocrinol Metab Bali A, Vanden Bergh P, Baron-Hay S, Scott C, 2006; 290(3):E471-9. Fink D, Hacker NF, Sutherland RL, O’Brien PM. 65. Latham CF, Lopez JA, Hu SH, Gee CL, A distinct molecular profile associated with Westbury E, Blair DH, Armishaw CJ, Alewood mucinous epithelial ovarian cancer. Br J Cancer PF, Bryant NJ, James DE, Martin JL. Molecular 2006; 94:904-913. dissection of the Munc18c/syntaxin4 interaction: 54. Henderson MJ, Munoz MA, Saunders DN, implications for regulation of membrane trafficking. Clancy JL, Russell AJ, Williams B, Pappin D, Khanna Traffic 2006; 7(10):1408-19. KK, Jackson SP, Sutherland RL, Watts CK. EDD 66. Lee H, Zahra D, Vogelzang A, Newton R, mediates DNA damage-induced activation of CHK2. Thatcher J, Quan A, So T, Zwirner J, Koentgen J Biol Chem 2006; 281(52):39990-40000. F, Padkjaer SB, Mackay F, Whitfeld PL, Mackay 55. Henshall SM, Horvath LG, Quinn DI, Eggleton CR. Human C5aR knock-in mice facilitate the SA, Grygiel JJ, Stricker PD, Biankin AV, Kench JG, production and assessment of anti-inflammatory Sutherland RL. Zinc-alpha2-glycoprotein expression monoclonal antibodies. Nat Biotechnol 2006; as a predictor of metastatic prostate cancer 24(10):1279-1284. following radical prostatectomy. 67. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, J Natl Cancer Inst 2006; 98(19):1420-1424. Shen Y, Ye JM, Lee CH, Oh WK, Kim CT, Hohnen- 56. Ho KK. Endocrinology: the next 60 years. Behrens C, Gosby A, Kraegen EW, James DE, Kim J Endocrinol 2006; 190(1):3-6. JB. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial 57. Ho KK, Gibney J, Johannsson G, Wolthers T. metabolic effects in diabetic and insulin-resistant Regulating of growth hormone sensitivity by sex states. Diabetes 2006; 55(8):2256-64. steroids: implications for therapy. Front Horm Res 2006; 35:115-28. 68. Lin EJ, Lee NJ, Slack K, Karl T, Duffy L, O’Brien E, Matsumoto I, Dedova I, Herzog H, Sainsbury A. 58. Hruban RH, Adsay NV, Albores-Saavedra Distinct endocrine effects of chronic haloperidol J, Anver MR, Biankin AV, Boivin GP, Furth EE, or risperidone administration in male rats. Furukawa T, Klein A, Klimstra DS, Kloppel G, Neuropharmacology 2006; 51(7-8):1129-36. 66 Lauwers GY, Longnecker DS, Luttges J, Maitra A, Offerhaus GJ, Perez-Gallego L, Redston M, Tuveson 69. Lin EJ, Sainsbury A, Lee NJ, Boey D, Couzens DA. Pathology of genetically engineered mouse M, Enriquez R, Slack K, Bland R, During MJ, models of pancreatic exocrine cancer: consensus Herzog H. Combined deletion of Y1, Y2, and Y4 report and recommendations. Cancer Res 2006; receptors prevents hypothalamic neuropeptide 66(1):95-106. Y overexpression-induced hyperinsulinemia despite persistence of hyperphagia and obesity. 59. Ishimaru N, Kishimoto H, Hayashi Y, Sprent Endocrinology 2006; 147(11):5094-101. J. Regulation of naive T cell function by the NF- kappaB2 pathway. Nat Immunol 2006; 7(7):763-72. 70. Lin EJ, Young D, Baer K, Herzog H, During MJ. Differential actions of NPY on seizure modulation 60. Jeffrey KL, Brummer T, Rolph MS, Liu SM, via Y1 and Y2 receptors: evidence from receptor Callejas NA, Grumont RJ, Gillieron C, Mackay F, knockout mice. Epilepsia 2006; 47(4):773-80. Grey S, Camps M, Rommel C, Gerondakis SD, Mackay CR. Positive regulation of immune cell 71. Lin S, Boey D, Lee N, Schwarzer C, Sainsbury function and inflammatory responses A, Herzog H. Distribution of prodynorphin mRNA by phosphatase PAC-1. Nat Immunol 2006; and its interaction with the NPY system in the 7(3):274-83. mouse brain. Neuropeptides 2006; 40(2):115-23. 61. Kanis JA, Johnell O, Oden A, Johansson 72. Liu SM, Xavier R, Good KL, Chtanova T, Newton H, Eisman JA, Fujiwara S, Kroger H, Honkanen R, Sisavanh M, Zimmer S, Deng C, Silva DG, Frost R, Melton LJ, 3rd, O’Neill T, Reeve J, Silman A, MJ, Tangye SG, Rolph MS, Mackay CR. Immune Tenenhouse A. The use of multiple sites for the cell transcriptome datasets reveal novel leukocyte diagnosis of osteoporosis. Osteoporos Int 2006; subset-specific genes and genes associated with 17(4):527-34. allergic processes. J Allergy Clin Immunol 2006; 118(2):496-503. 62. Kohonen-Corish MRJ, Cooper WA, Saab J, Thompson JF, Trent RJA, Millward MJ. Promoter hypermethylation of the O6-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma. J Invest Dermatol 2006; 126:167-171. Clin Lab osteoporosis and patientswithPaget’s disease. osteoclastic activityinwomen withpostmenopausal Serum cathepsinKconcentrations reflect Winter J, Nguyen TV, DunstanCR,Seibel MJ. 83. 102:147-155. in breastcancer. RL. c-Mycoverexpression andendocrineresistance CJ, ButtAJ,HenshallSM,Musgrove EA,Sutherland Kench JG,AllesMC,Gardiner-Garden M,Ormandy CK, EggletonSA,MurphyNC,MillarEKA,CreaP, 82. 2006. p.e20(pages1of4). (BCO) human breastcancercells.In: estrogen signallingandantiestrogenresistancein suppresses p21WAF1/CIP1 expression during 81. AIDS men--a randomized,placebo-controlledstudy. markers ofcardiovascular diseaseinHIV-infected A. Effectofpravastatin onbodycompositionand Norris R,SamarasK,Feneley MP, CooperDA, Carr 80. 18(5):284-9. system onTcellfunction. 79. 2006; 18(5):261-2. BLyS family:arewe thereyet? 78. Elsevier; 2006.p.237-248. Mackay I,editors. and Treatment ofAutoimune Diseases.In:RoseN, Molecules andChemoattratantsinthePathogenesis 77. protein 70. innate immunity--binding tobacterialheatshock 76. Cancer Therapy. Receptor withAgonistAntibodiesasaPotential R, Browning JL. Targeting theLymphotoxin-{beta} Meier W, Violette SM,Mackay F, Yang D,Hoffman Miatkowski K,AmatucciJ,Crowell T, PrenticeH, E, Yang W, JarpeM,Fawell S,ReffM,CarmilloA, Bottiglio C,DingJ,GriffithL,Heaney G,Silverio N, Perrin S,XuX,SzeligaK,Wortham K,Kelly R, Garber E,LukashinA,Ngam-EkZengW, Allaire 75. 2006; 177(3):1492-9. degranulation ofRBL-2H3 mastcells. beta IIandcoincideswiththeonsetofstimulated IIA onSer1917ismediatedbyproteinkinaseC Phosphorylation ofnonmusclemyosin heavy chain JR, Schmitz-Peiffer C,HughesWE,BidenTJ. 74. 55(9):2491-501. role forA20inbeta-cellprotection. factor-kappaB regulatesbeta-celldeath:acritical Walters SN,MarinoE,McSheaA,Grey ST. Nuclear 73. Garvan Institute Publications 2006 MeierC,MeinhardtU,Greenfield JR,De Liuwantara D,Elliot M,SmithMW, Yam AO, Mackay F, LeungH.The roleoftheBAFF/APRIL Mackay F, CancroMP. Travelling withtheBAFF/ Mackay CR,Von AndrianUH.Adhesion Mackay CR,SallustoF. Anew roleforCCR5in Lukashev M,Lepage D,Wilson C,BaillyV, Ludowyke RI,ElgundiZ,KranenburgT, Stehn McNeilCM,SergioAndersonLR,Inman McNeilCM,Musgrove EA.Review of:c-MYC MallonPW, Miller J,Kovacic JC,Kent-Hughes J, 2006;20:1003-10. www.bco.org: CambridgeUniversity Press; 2006;52(1-2):1-10. Eur JImmunol Cancer Res J Steroid BiochemMolBiol The Autoimmune Diseases Semin Immunol 2006;36(9):2293-5. 2006;66(19):9617-24. Breast CancerOnline Semin Immunol Diabetes J Immunol 2006; 2006; 2006; . 4ed:

factors andsporttypeongrowth hormone- Kazlauskas R,HoKK.Influenceofdemographic Trout GJ,Seibel MJ,BaxterRC,HandelsmanDJ, 89. Eur JNutr growth depends on thelevel ofcyclinD1. Lycopene inhibitionofIGF-inducedcancercell Watts CKW, SutherlandRL,Levy J,SharoniY. 88. Factors signaling andoncogenictransformation. 87. Diabetes high-fat diet-induced obesityandinsulinresistance. lymphoma-deficient miceareprotectedagainst Laybutt R,Cooney GJ,JamesDE.Casitasb-lineage 86. 2006; 55(12):3411-7. expenditure and improved insulinaction. ubiquitin ligasedomainresultsinincreasedenergy James DE,Cooney GJ.Geneticablationofthec-Cbl 85. (Oxf) hormone actionbysex steroids. 84. protein. with impairedrepair capabilityofthemutated MSH2 missensemutationsis typicallyassociated A, GreenblattM,NystromM. Pathogenicity of Gerdes A-M, Peltomaki P, Mangold E, de la Chapelle H, Holinksi-Feder E,MacraeF, Kohonen-Corish M, 96. Breast CancerRes of lobuloalveoli fromductalepithelium. cues andcellfatedecisionsthatdrive theformation The alveolar switch: coordinatingtheproliferative 95. Endocrinol Metab metabolic inflexibility indiabetes. and invivo applicationrevealing profound metabolism inmice:tracermethoddevelopments Larsen T, FurlerSM,LjungB,Severson D. Cardiac 94. J Musculoskelet Neuronal Interact of osteoporosis:opportunitiesandchallenges. 93. 21(2):340-9. analysis ofclinicaltrials. fracture efficacyofbiophosphonates:aBayesian 92. Int JEpidemiol defects: systematicreview andmeta-analysis. Association between AgentOrangeandbirth 91. 2006; 36(7):1837-46. Toll-like receptor-activated B-1cells. J, XuS,Mackay F, LamKP. BAFF costimulationof 90. J ClinEndocrinolMetab responsive markers ineliteathletes. Nguyen TV, EismanJA.Pharmacogenomics NelsonAE,Howe CJ,Nguyen TV, LeungKC, NahumA,ZellerL,Danilenko M,PrallOWJ, Musgrove EA.Cyclins:rolesinmitogenic MoleroJC,Waring SG,CooperA,Turner N, MoleroJC,Turner N,Thien CB,LangdonWY, MeinhardtUJ,HoKK.Modulationofgrowth OllilaS,SarantausL,Kariola R, ChanP, Hampel Oakes SR,HiltonHN,OrmandyCJ. Oakes ND,Thalen P, AasumE,Edgley A, Nguyen ND,EismanJA,Nguyen TV. Anti-hip NgoAD,Taylor R,RobertsCL,Nguyen TV. NgLG,CH,Woehl B,SutherlandAP, Huo 2006;65(4):413-22. 2006;24(01):13-19. Gastroenterology 2006;55(3):708-15. 2006;45(5):275-282. 2006;35(5):1220-30. 2006;290(5):E870-81. 2006;8:207-217. 2006;91(11):4424-32. J BoneMinerRes 2006;131:1408-1417. Clin Endocrinol 2006; 6(1):62-72. Am JPhysiol

Eur JImmunol

Growth Diabetes

2006;

PUBLICATIONS Publications

97. Parker SK, Williams HM, Turner N. Modeling the 110. Rizzoli R, Eisman JA, Norquist J, Ljunggren antecedents of proactive behavior at work. J Appl O, Krishnarajah G, Lim SK, Chandler J. Risk factors Psychol 2006; 91(3):636-52. for vitamin D inadequacy among women with osteoporosis: an international epidemiological 98. Parkes HA, Preston E, Wilks D, Ballesteros study. Int J Clin Pract 2006; 60(8):1013-9. M, Carpenter L, Wood L, Kraegen EW, Furler SM, Cooney GJ. Overexpression of acyl-CoA synthetase- 111. Rolph MS, Sisavanh M, Liu SM, Mackay CR. 1 increases lipid deposition in hepatic (HepG2) cells Clues to asthma pathogenesis from microarray and rodent liver in vivo. Am J Physiol Endocrinol expression studies. Pharmacol Ther 2006; 109(1- Metab 2006; 291(4):E737-44. 2):284-94. 99. Pau H, Fagan P, Oleskevich S. Locating 112. Rubinstein MP, Kovar M, Purton JF, Cho JH, the scala media in the fixed human temporal Boyman O, Surh CD, Sprent J. Converting IL-15 to bone for therapeutic access: a preliminary study. a superagonist by binding to soluble IL-15Ralpha. J Laryngol Otol 2006:1-2. Proc Natl Acad Sci U S A 2006; 103(24):9166-71. 100. Peake PW, Shen Y, Campbell LV, Charlesworth 113. Sainsbury A, Bergen HT, Boey D, Bamming JA. Human adiponectin binds to bacterial D, Cooney GJ, Lin S, Couzens M, Stroth N, Lee NJ, lipopolysaccharide. Biochem Biophys Res Commun Lindner D, Singewald N, Karl T, Duffy L, Enriquez R, 2006; 341:108-15. Slack K, Sperk G, Herzog H. Y2Y4 receptor double knockout protects against obesity due to a high-fat 101. Phan TG, Paus D, Chan TD, Turner ML, Nutt diet or Y1 receptor deficiency in mice.Diabetes SL, Basten A, Brink R. High affinity germinal center 2006; 55(1):19-26. B cells are actively selected into the plasma cell compartment. J Exp Med 2006; 203(11):2419-24. 114. Samaras K, McElduff A, Twigg SM, Proietto J, Prins JB, Welborn TA, Zimmet P, Chisholm DJ, 102. Pongchaiyakul C, Apinyanurag C, Soontrapa Campbell LV. Insulin levels in insulin resistance: S, Soontrapa S, Pongchaiyakul C, Nguyen TV, phantom of the metabolic opera? Med J Aust 2006; Rajatanavin R. Prevalence of osteoporosis in Thai 185(3):159-61. men. J Med Assoc Thai 2006; 89(2):160-9. 115. Severi G, Hayes VM, Neufing P, Padilla EJD, 103. Pongchaiyakul C, Nguyen TV, Kosulwat Tilley W, Eggleton SA, Morris H, English DR, V, Rojroongwasinkul N, Charoenkiatkul S, Southey MC, Hopper JL, Sutherland RL, Boyle P, Sanchaisuriya P, Rajatanavin R. Defining obesity Giles GG. Variants in the prostate-specific antigen by body mass index in the Thai population: an (PSA) gene and prostate cancer risk, survival and epidemiologic study. Asia Pac J Clin Nutr 2006; circulating PSA. Cancer Epidemiol Biomark Prev 15(3):293-9. 2006; 15(6):1142-1147. 104. Pongchaiyakul C, Pongchaiyakul C, 116. Shane E, Goldring S, Christakos S, Drezner M, Wanothayaroj E, Nguyen TV, Rajatanavin R. Eisman J, Silverman S, Pendrys D. Osteonecrosis of Association between waist circumference and the jaw: more research needed. J Bone Miner Res percentage body fat among rural Thais. 68 2006; 21(10):1503-5. J Med Assoc Thai 2006; 89(10):1592-600. 117. Shane EJ, Christakos S, Goldring SR, Lorenzo 105. Ramm G, Larance M, Guilhaus M, James JA, Hasson KR, Drezner MK, Raisz LG, Eisman JA. DE. A role for 14-3-3 in insulin-stimulated GLUT4 Biomedical, academic, and industry interaction. translocation through its interaction with the J Bone Miner Res 2006; 21:353. RabGAP AS160. J Biol Chem 2006; 281(39):29174-80. 118. Shum BO, Mackay CR, Gorgun CZ, Frost MJ, Kumar RK, Hotamisligil GS, Rolph MS. The 106. Rand KN, Mitchell SM, Clark SJ, Molloy PL. adipocyte fatty acid-binding protein aP2 is required Bisulphite differential denaturation PCR for analysis in allergic airway inflammation.J Clin Invest 2006; of DNA methylation. Epigenetics 2006; 1(2):94-100. 116(8):2183-2192. 107. Rasiah KK, Kench JG, Gardiner-Garden M, 119. Silveira PA, Chapman HD, Stolp J, Johnson E, Biankin AV, Golovsky D, Brenner PC, Kooner R, Cox SL, Hunter K, Wicker LS, Serreze DV. Genes O’Neil GF, Turner JJ, Delprado W, Lee CS, Brown within the Idd5 and Idd9/11 Diabetes Susceptibility DA, Breit SN, Grygiel JJ, Horvath LG, Stricker PD, Loci Affect the Pathogenic Activity of B Cells Sutherland RL, Henshall SM. Aberrant neuropeptide in Nonobese Diabetic Mice. J Immunol 2006; Y and macrophage inhibitory cytokine-1 expression 177(10):7033-41. are early events in prostate cancer development and are associated with poor prognosis. Cancer 120. Silveira PA, Grey ST. B cells in the spotlight: Epidemiol Biomarkers Prev 2006; 15(4):711-716. innocent bystanders or major players in the pathogenesis of type 1 diabetes. Trends Endocrinol 108. Reid IR, Cornish J, Baldock PA. Nutrition- Metab 2006; 17(4):128-35. related peptides and bone homeostasis. J Bone Miner Res 2006; 21(4):495-500. 121. Silveira PA, Serreze DV, Grey ST. Invasion of the killer B’s in Type 1 Diabetes. Frontiers 109. Rentero C, Evans R, Wood P, Tebar F, Vila de in Biosciences 2006; 12:2183-2193. Muga S, Cubells L, de Diego I, Hayes TE, Hughes WE, Pol A, Rye KA, Enrich C, Grewal T. Inhibition of H-Ras and MAPK is compensated by PKC- dependent pathways in annexin A6 expressing cells. Cellular Signalling 2006; 18(7):1006-16. Pharmacol the substituted-cysteine accessibilitymethod. N-methyl-D-aspartate receptor desensitizationwith Heinemann SF, Vissel B,Westbrook GL.Probing 136. 2006; 7:33. data enrichmentandexploration. BMC for customisedgenetranscriptmodelling,annotation- Schofield PR,Kapoor V, ChurchWB.DjinnLite:atool 135. glycogen synthase. is associatedwithsubcellularredistributionof of glycogensynthesisbyincreasedlipidavailability 134. 2006. p.139-157. Diseases. 4thed: In: RoseN,Mackay I,editors.The Autoimmune 133. 2006; 18(5):305-17. APRIL andhumanBcelldisorders. 132. (Aimspro®): Hopeorhype? 131. Pharmacol Ther autoimmune diseasesandlymphomas. Targeting BAFF: Immunomodulation for 130. memory Tcells. 129. 2006; 211:154-63. Homeostasis ofmemoryTcells. 128. 2006; 117(3):635-41. of allergicairway disease. reducing immunosuppressioninamousemodel Cyclophosphamide augmentsinflammationby 127. Comp Neurol I. Distributionincellbodiesandnerve terminals. Y2 receptorproteinexpression inthemousebrain. Herzog H,HokfeltT. Characterizationofneuropeptide 126. 177(3):1381-91. 1971. selective recruitment ofcirculatinglymphocytes. 125. 2006; 33:708–713. and unsaturatedfattyacids. vasodilation inrats:differentialrolesofsaturated High fatfeedingreducesendothelium-dependent 124. 2006; 44(7):345-53. of conditionalpointmutantknockinmice. 123. Prev ductal adenocarcinoma. AV. CyclinEexpression andoutcomeinpancreatic Sutherland RL,HenshallSM,Musgrove EA,Biankin 122. Garvan Institute Publications 2006 Tangye SG,Mackay F. Bcellsandautoimmunity. Teber ET, Crawford E,BoltonKB,Van DykD, Taylor AJ,Ye JM,Schmitz-Peiffer C.Inhibition Tangye SG,Bryant VL,CussAK,GoodKL.BAFF, Sutton I, Kermode AG. Hyperimmune goat serum SutherlandAP, Mackay F, Mackay CR. Skvorak K,Vissel B,HomanicsGE.Production Thomas CG,KruppJJ,Bagley EE,BauzonR, SurhCD,SprentJ.OntheTRAILofhomeostatic SurhCD,Boyman O,PurtonJF, SprentJ. SuYC,RolphMS,Cooley MA,Sewell WA. StanicD,Brumovsky P, Fetissov S,Shuster SprentJ,MillerJF, MitchellGF. Antigen-induced SongGY, GaoY, DiYW, Pan LL,ZhouY, Ye JM. SkalickyDA, Kench JG,SegaraD,ColemanMJ, 2006;15(10):1941-1947. J Immunol 2006;69(4):1296-303. 2006;499(3):357-90. 2006;112(3):774-86. Nat Immunol 2006; Elsevier AcademicPress (USA) J Endocrinol

Cancer EpidemiolBiomark J AllergyClinImmunol J ClinNeurosci Clin ExpPharmPhysiol 2006;7(5):439-41. Immunol Rev 2006;188(1):11-23. Semin Immunol Bioinformatics

Genesis 2006.

Mol

;

2006; 188:210-5. and theserotonintransportergene. Schofield PR.Life events, firstdepressiononset A, Wedgwood L,ScimoneA,BlairIP, Parker G, 141. (DOES). the DubboOsteoporosisEpidemiologyStudy density andfractureriskinelderlymenwomen: receptor gene,bodymassindex, bonemineral JA, CenterJR,Nguyen TV. Beta3-adrenergic 140. Opin ClinNutrMetabCare performance andmetabolismacrossspecies. 139. Neuroscience than inrats:correlationwithY2receptorplasticity. synaptic transmissionlesseffectively inmice Neuropeptide Yregulatesrecurrentmossyfiber 138. Int JBiochemCellBiol are independentofcytoskeletal integrity. function ofinsulinreceptorsubstrate-1(IRS-1) The subcellularfractionationpropertiesand C, RammG,JamesDE,Whitehead JP. 137. 49:1254-63. secretion inmouseislets. induction ofoxidative stressandimpairedinsulin S. The influenceofgeneticbackgroundonthe Kebede M,DunlopME,ProiettoJ,Andrikopoulos 146. 55(10):2797-804. uptake inhigh-fat-fed rats. mediated muscleandadiposetissueglucose enhances acuteAMP-activated proteinkinase- Kemp B,KraegenE.Rosiglitazonetreatment 145 2006; 168(2):255-60. and Y4receptorknockout mice. of darkphasewater intake inneuropeptide-Y Y2 Herzog H,Peskar BA, HolzerP. Selective increase 144. 2(2):172-186. pockets ofhypomethylation. transcriptional activityatthecentromerethrough Craig JM,SongJZ,ClarkSJ,ChooKHA.Permissive 143. Dev Biol vascularization ofthemouseplacenta. Loss ofCited2affectstrophoblastformationand Sparrow DB,Martinez,BarberaJP, Dunwoodie SL. Lopes FloroK,PreisJI,MichalicekJ,Maclean 142. . Ye JM,Dzamko N,Hoy AJ,IglesiasMA, Turner N,HulbertA,ElsePL.Limitstophysical Tu B,JiaoY, HerzogH,NadlerJV. Thomas EC,ZheY, MoleroJC,Schmitz-Peiffer Wong NC,Wong LH,QuachJM,CanhanP, Wilhelm K,MitchellPB,Niven H,Finch Wang CY, Nguyen ND,MorrisonNA,Eisman ZraikaS,Aston-Mourney K,Laybutt DR, Wultsch T, Painsipp E,DonnerS,SperkG, Withington SL,ScottAN,Saunders DN, BMC MedGenet 2006; 294(1):67-82. 2006;143(4):1085-94. 2006;38(10):1686-99. 2006;7:57. Diabetologia Diabetes 2006;9(6):691-696. PLOS Genetics Behav Brain Res 2006; Br JPsychiatry 2006;

2006;

Curr

PUBLICATIONS FINANCIALS 70 of the Australian Equivalents to International FinancialReporting Standards.of theAustralianEquivalents toInternational The figures from 2003onwards reflect theadjustments in respectofthe adoption Garvan Institute of Medical Research Financial Highlights Carried Forward Accumulated Surplus/(Deficit) Transfer toInfrastructure ExpenseReserve Transfer from/(to) Endowment Reserve Transfer from/(to) ResearchProgramReserve Accumulated DeficitBrought Forward Net Income/(Loss) Endowment Earnings Endowment Grants Transfer from BuildingMaintenanceReserve Transfer from/(to) BuildingReserve Building AssetAmortisation Total Operating Expenses Building andScientificOperations Administration andInformationTechnology Capital Equipment Research Expenditures Remuneration Costs Total Operating Income Other Income Garvan ResearchFoundation Commercial Collaborations Commonwealth Government Grant NSW Government Grant Other grants Other Peer Reviewed Grants NHMRC Grants Income Statement

2,770 (3,602) 22,325 20,816 (3,173) (4,247) (1,171) 12,577 $’000 3,569 1,822 1,938 3,597 3,638 6,810 2,181 2,144 1,225 4,198 1,146 3,583 1,047 2002 241 473 249 - -

2,016 25,327 27,076 (2,122) (3,602) (1,171) 14,367 $’000 4,417 2,054 2,116 2,395 4,433 2,800 2,141 5,229 5,636 8,465 2,398 1,047 (797) 2003 751 510 394

- - -

(3,247) (1,285) 27,220 24,346 (1,171) 14,879 $’000 1,891 2,394 3,202 4,854 2,579 1,671 1,269 2,880 6,222 9,244 1,250 1,047 2004 (582) (797) (583 463 481 - - -

(3,514) 29,088 30,025 (1,726) (1,110) (3,247) (1,171) 17,377 12,080 $’000 2,569 2,378 2,931 1,896 4,506 2,774 2,343 2,043 3,720 6,865 1,011 1,047 2005 200 745 - - -

(11,809) 36,927 49,114 22,809 (1,552) (3,514) (1,353) (1,171) 21,983 12,174 13,832 10,965 5,827 $’000 2,181 2,438 3,913 2,986 5,607 2,916 2,562 4,091 4,700 8,184 2006 (107) 655 -

Garvan Institute of Medical Research Financial Highlights of the Australian Equivalents to International FinancialReporting Standards.of theAustralianEquivalents toInternational The figures from 2003onwards reflect theadjustments in respectofthe adoption Total NetFunds Reserves Accumulated Deficit Total Liabilities Borrowings Provisions Current Liabilities Total Assets Investments atMarket Value Building andLand Current Assets Balance Sheet 38,897 11,052 49,949 (3,602) 42,499 39,712 $’000 6,000 1,778 3,274 7,199 3,038 2002 42,267 10,713 52,980 43,064 38,541 $’000 6,000 2,220 2,493 9,321 5,118 2003 (797)

39,936 11,010 50,946 (3,247) 43,183 37,371 $’000 6,000 2,061 2,949 9,903 3,672 2004 41,458 12,004 53,462 (3,514) 44,972 11,630 36,200 $’000 6,000 2,457 3,547 5,632 2005

65,620 10,032 75,651 59,793 20,536 36,879 18,236 $’000 5,827 3,069 6,963 2006 -

FINANCIAL REPORT FINANCIALS 72 Net Assets Less: Liabilities Assets Represented By: Accumulated FundsCarriedForward Total Grants Endowment Funds Specific Research General Research Funds Available for Grants toinsitutefor: Accumulated FundsPriorYears Net FundsRaised Public Awareness Program Fundraising Expenses Total Income Interest andOtherincomet Bequests Events Donations &Pledges Statement ofFunds of the Australian Equivalents to International FinancialReporting Standards.of theAustralianEquivalents toInternational The figures from 2003onwards reflect theadjustments in respectofthe adoption Garvan Research Foundation Financial Highlights

1,521 2,224 $’000 3,717 3,700 4,186 3,876 2,378 (159) 2002 (159) 448 748 750 416 429 270 17 38 25

5,187 $’000 4,246 4,405 4,057 1,204 3,313 2,003 2003 (159) 721 189 850 881 949 259 189

61 44 70

263 $’000 3,051 2,862 3,560 2,921 3,276 1,104 1,250 2004 642 130 567 189 197 130 56 17 67 4

3,760 $’000 3,217 3,087 3,088 1,493 2,524 2005 607 129 850 130 928 266 182 129 745 66 42 53

13,605 13,476 14,494 13,527 10,315 10,965 $’000 1,018 1,691 3,826 2006

173 251 871 129 332 78 78 21

The Garvan’s mission is to make significant Project Manager Dr Branwen Morgan contributions to medical science that will Design + Production change the directions of science and medicine Turnbull Ossher Design and have major impacts on human health. Photography Garvan strives to enhance and develop Richard Weinstein Photography research programs that combine fundamental Published April 2007 science with strong clinical interactions. We wish to acknowledge Turnbull Ossher Design for the generous gift of the Annual Report 2006 design and thank them for their continuing and valuable support.

Further Acknowledgements Garvan Research Foundation

During 2007, further website changes will be made to reflect the more efficient and increased use of the online medium. Annual Report 2006 Annual Report 2006

Annual Report 2006